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 Abstract 
Metal ions play essential roles in biological functions including catalysis, protein 
stability, DNA-protein interactions and cell signaling.  It is estimated that 30% of 
proteins utilize metals in some fashion.  Additionally, methods by which metal 
ions can be visualized have been utilized to study metal concentrations and 
localizations in relation to disease.  Understanding the roles metals play in 
biological systems has great potential in medicine and technology. 
Chapters 1 and 2 of this dissertation analyzes the structure and function of the 
Mn-dependent enzyme oxalate decarboxylase (OxDc) and Chapter 2 presents a 
bioinformatic analysis of the cupin superfamily that provides the structural 
scaffold of the decarboxylase.  The X-ray crystal structure of the W132F variant 
was determined and utilized together with EPR data to develop a computational 
approach to determining EPR spectra of the enzyme’s two metal-binding centers.  
Furthermore, a variant in which the catalytic Glu162 was deleted revealed the 
binding mode of oxalate in the first substrate-bound structure of OxDc.  OxDc is a 
member of the cupin superfamily, which comprises a wide variety of proteins and 
enzymes with great sequence and functional diversity.  A bioinformatic analysis 
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of the superfamily was performed to analyze how sequence variation determines 
function and metal utilization. 
Chapters 3 and 4 discuss the expansion of lanthanide-binding tags (LBTs) to in 
cellulo studies.  Lanthanide-binding tags are short sequences of amino acids that 
have high affinity and selectivity for lanthanide ions.  An EGF-LBT construct used 
to quantify EGF receptors on the surface of A431 and HeLa cells.  The results 
from the LBT quantification are consistent with previous studies of EGFR 
receptors in these cell types, validating the use of this method for future studies.  
The potential of using LBTs for X-ray fluorescence microscopy (XFM) was also 
investigated.  LBT-labeled constructs were utilized to determine if membrane-
bound as well as cytosolic LBT-containing proteins could be visualized and 
localized to their cell compartments via XFM; both membrane-localized and 
cytosolic proteins were successfully visualized.  With the high resolution (< 150 
Å) obtainable with new synchrotron beamline configurations LBTs could be used 
to study nanoscale biological structures in their near-native state. 
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Chapter 1: Chapter 1: Crystallographic studies of oxalate decarboxylase  
1.1 Introduction and literature review  
1.1.1  Introduction 
Oxalate is produced as a byproduct of normal cellular metabolism or 
consumed directly through diet1.  High levels of oxalate is toxic in nearly all 
species2,3.  Plants, fungi and bacteria have developed pathways to breakdown 
oxalate4–8. However, mammals, including humans, do not produce enzymes that 
break down toxic oxalate and rely on the gut flora to break down oxalate into 
non-toxic byproducts.1,9,10  Excess levels of oxalate results in formation of 
insoluble oxalate salts.  Typically, these insoluble salts are excreted in the urine 
as microcrystals but high levels of insoluble oxalate salts can result in kidney 
stone formation.9  Understanding the enzymes involved in oxalate degradation 
has applications in material science where oxalate degrading enzymes have 
been investigated as tools for removing excess oxalate produced in paper 
production11, and diagnostics and biotherapuetics for chronic kidney stones12. 
This chapter will focus on structure-based studies of oxalate decarboxylase from 
Bacillus subtilis, a Gram-positive soil bacterium.  
1.1.2  The enzymes of oxalate metabolism 
Plants, bacteria and fungi have evolved four classes of oxalate 
metabolizing (Figure 1.1)8. The four enzymes classes differ in the products 
produced from oxalate, cofactor utilized and species in which they are used 
(Figure 1.1). Oxalyl-CoA decarboxylase (OXC) is an enzyme found primarily in 
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bacteria with a few orthologs found in select plant species.13  OXC utilizes a 
thiamine pyrophosphate (TPP) cofactor to facilitate the decarboxylation of 
oxalate producing CO2 and formyl-CoA.14  Oxalate oxidoreductase (OOR),  
second oxalate-degrading enzyme class,  also uses TPP as a cofactor and to 
date has only been identified in the anaerobic acetogen, Moorella 
themoacetica.15  This unique enzyme is composed of three subunits that oxidize 
oxalate coupled with the production of CO2 or bicarbonate and 2 electrons.  OOR 
in addition to requiring a TPP cofactor also  contains three [4Fe-4S] clusters.   
The other two classes of oxalate-degrading enzymes are both Mn(II) dependent.  
Oxalate oxidase (OxOx) is used in plants and fungi to break down oxalate to two 
CO2 and one H2O2.  Oxalate decarboxylase (OxDc), found in fungi and few 
bacteria, utilizes Mn(II) and O2 to convert oxalate to one CO2 and formate.  Whil 
each of the four classes of oxalate degrading enzymes produce CO2,  they differ 
in the cofactors required for catalysis as well as the species in which they are 
found.  The remainder of this chapter will focus on OxOx and OxDc.  
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 Figure 1.1: Enzymes of oxalate metabolism 
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1.1.3 Comparison of OxDc and OxOx 
 Both oxalate oxidase (OxOx) and oxalate decarboxylase (OxDc) belong to 
the cupin superfamily and use a Mn(II) metal ion cofactor (Figure 1.1).  The cupin 
superfamily is a very functionally diverse superfamily of proteins and is found in 
all domains of life.  The cupin superfamily contains a conserved beta-barrel fold.  
OxOx orthologs can either be monocupins such as in Hordeum vulgare (Hv) or 
bicupins with two consecutive cupin domains such as the Ceriporiopsis 
subvermispora OxOx ortholog, while OxDc is a bicupin.  Bs OxDc and Hv OxOx 
share 17% sequence identity and the Cs OxOx and Bs OxDc share 49% 
sequence identity.  (Appendix I) While the crystal structure of the monocupin Hv 
OxOx is available there is no crystal structure for the Cs OxOx ortholog.  A 
homology model of Cs OxOx based upon Bs OxDc (PDB 1J58) shows a high 
level of structural similarity (Figure 1.2).  The Cs is a better model for comparison 
to OxDc than the Hv ortholog given their higher sequence similarity and predicted 
structural similarity. Given the sequence and structural similarity, it is suspected 
that the two share a common ancestor16,17.  
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Figure 1.2) Structural overlays of Bs OxDc (PDB ID 1UW8; blue) and homology model of Cs OxOx  
(red). Mn(II) ions are shown in purple. 
 
 
 
 
 6 
  The Mn(II) binding sites for OxDc and OxOx are identical (Figure 
1.3) yet they convert oxalate into different products.  It has been proposed that 
the differentiation of product formation is due to the presence an active-site base 
in OxDc to protonate a formyl radical intermediate18.  The plant forms of OxOx 
have low sequence similarity to Bs OxDc but high sequence simlairty when 
compared to each other (Appendix II).  However, the fungal Cs OxOx has 
significantly higher sequence similarity, 58%, to Bs OxDc.  Previous studies show 
that engineering of a chimeric mutant in which the catalytic residues of Bs OxDc 
have been substituted with the cognate residues in the bicupin Ceriporiopsis 
subvermispora  OxOx results in a specificity switch for product formation, 
meaning the chimeric OxDc will have produce two CO2 and H2O218. 
Understanding the details of the catalytic steps of the chimeric enzyme may allow 
for an understanding of how changes in active site environment of these very 
similar enzymes allows for product formation specificity.  
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Figure 1.3: Mn(II)-binding sites for A) Bs OxDC (PDB ID 1UW8) and B) Hv 
OxOx (PDB ID 2ETE) 
 
 
 
 8 
Kinetic and structural studies of Bs OxDc have identified an active site “lid” 
comprised of residues 161-164.  This lid is termed the SENS loop for the 
sequence of residues (S161E162N163S164).  Within the SENS loop, Glu162 has 
been identified as essential for catalytic activity in OxDc19–23.   It is believed that 
Glu162 is involved in two proton coupled electron transfer (PCET) steps that 
results in the formation of formate as a product21.  The SENS loop has been 
observed in two conformations in crystal structures (Figure 1.4A).[R]  In one 
form, the “open” form, Glu162 is flipped out of the active site and formate 
occupies the active site, coordinated to the Mn(II) ion.  In the “closed” form 
Glu162 is flipped into the active site (Figure 1.4B). Thus far, no product or buffer 
molecules bound in the active have been observed in the closed form of the 
enzymes.  If Glu162 is involved in a PCET step, it cannot occupy the “open” 
conformation during catalysis.  However it is possible that Glu162 plays a role 
other than acting as an active site acid and/or base.  The oxalate-bound structure 
of OxDc would help to identify the position of Glu162 in the catalytically 
competent conformation of the SENS loop and help clarify the role Glu162 plays 
in catalysis. 
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Figure 1.4: A) Closed (PDB ID 1J58; blue) and open (PDB ID 1UW8; pink) structures of OxDc. The SENS loop is 
highlighted in the box. B) Overlay of the active sites of structures with closed and open conformations of Glu162 
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   It has been observed that both OxDc and OxOx have small amounts of 
the other activity24,25.  Given the high level of sequence similarity between Bs 
OxDc and Cs OxOx, the role Glu162 plays in the proposed PCET steps has been 
studied in context of mutants in which the SENS loop of OxDc has been replaced 
by the cognate residues in Cs OxOx.  In the “chimeric” form of OxDc the SENS 
loop is replaced by the OxOx catalytic loop residues D241A242S243N244. Initial 
studies of a chimeric mutant of OxDc in which SENS loop residues were 
replaced by DASN showed a reaction specificity switch of 225,000-fold for 
increased oxidase activity26.  When the catalytic Glu residue is replaced in the 
chimeric sequence (DESN), the specificity switch for oxidase activity decreases 
to 2500-fold26.  These results were interpreted to mean that the first steps leading 
to decarboxylation in OxDc and OxOx must be the same and that protonation of 
the formyl radical intermediate by Glu162 of OxDc leads to product specificity 
(Scheme 1).   
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Scheme 1: Hypothetical scheme showing how initial steps of decarboxylation 
in OxOx and OxDc are similar followed by differentiation by protonation of 
formyl radical intermediate by Glu162 for OxDc. 
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 In collaboration with the laboratory of Nigel Richards at Indiana 
University–Purdue University Indianapolis (IUPUI), we have sought to determine 
the exact mechanistic details for the specificity switch.  Our collaborators utilized 
membrane inlet mass spectrometry (MIMS) and kinetic isotope effects (KIE) on 
chimeric OxDc/OxOx SENS/DASN loop variants. The DASN variant showed 
decreased decarboxylase activity (~17 M-1s-1 vs 5700 M-1s-1 for WT OxDc) but 
showed a specificity switch of 14,100 fold27.  However, measurement of reaction 
stoichiometry as a function of oxalate concentration by MIMS show that the 
observed oxidase activity for the DASN variant arises from only 9% of the 
enzyme present in solution27.  Thus, the majority of the protein molecules 
perform decarboxylase functions, albeit much less efficiently than wtOxDc.  This 
was interpreted to mean that replacement of the loop residues with OxOx 
cognate residues does not modulate the chemistry of the enzyme.  Instead, it is 
likely that the observed oxidase activity likely arises from increased solvent 
access to the active site.  Kinetic isotope effects indicate that the C-C bond 
cleavage steps leading up to decarboxylation are identical for the DASN OxDc 
variant and the wild-type OxDc, This again suggests that product specificity 
occurs after the formation of the radical intermediate and also implies that 
Glu162 is not involved in the initial deprotonation of oxalate. If oxidase activity 
results from solvent access due to reduced bulk given the Glu to Ala difference, 
and OxDc and OxOx share common steps leading to the same formyl radical 
intermediate (Scheme 2), this raises the question as to the true function of 
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Glu162. It is likely that Glu162 serves to regulate loop conformation in order to 
exclude solvent access to the active site in order to “protect” the intermediate.  
However, it may still play a role in protonation of the formyl radical intermediate 
to produce formate.  We sought to determine the substrate-bound form of OxDc 
in order to determine the catalytically competent form of the enzyme, the 
substrate-binding mode of OxDc, and the conformation of the SENS loop in the 
presence of substrate.  
1.1.4 Additional questions to be answered 
In addition to our work in achieving a substrate-bound structure of OxDc, 
we also wished to determine the structure of a variant in which the hydrogen 
bonding network surrounding the Mn(II) ion had been slightly modified.  As 
previously mentioned, OxDc is a bicupin and coordinates a Mn(II) ion in both the 
N-terminal domain (NTD) and C-terminal domain (CTD).  Both Mn(II) ions are 
coordinated with identical geometry (Figure 1.5A and B).  To explore the effects 
of altering the hydrogen-bonding network of the residues around the metal center 
a W132F mutant was cloned by Whitney Kellet. Work by our collaborators in the 
Richards laboratory showed that the W132F variant had a significantly different 
EPR fine structure signature for the Mn(II) ion in the NTD of OxDc.  The changes 
in the EPR signature was attributed to the loss of a hydrogen bond between 
W132 and E101, that is coordinated to the Mn(II) ion (Figure 1.5C).  The goal of 
this work was to provide coordinates for the W132F variant in order to develop a 
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theoretical model for calculating EPR fine structure parameters of other OxDc 
variants.   
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Figure 1.5) OxDc metal-binding sites A) NTD Mn(II) binding site 
showing hydrogen-bonding interaction between E101 and W132. B) 
CTD Mn(II) binding site showing hydrogen bonding interaction between 
E280 and Q282.  
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1.2 Materials and Methods 
1.2.1 Expression of Bs OxDc 
Plasmids carrying the different OxDc variants were provided by the 
laboratory of Nigel Richards, IUPUI.  OxDc variants were expressed in E. coli 
BL21(DE3) cells bearing the pET32a plasmid coding for OxDc grown in luria 
broth supplemented with ampicillin at 37° C.  At an OD600 of 0.6-0.8, the cells 
were induced with 1 mM IPTG and 5 mM CoCl2 to substitute for Mn(II).   The 
cells were heat shocked by increasing the shaker temperature to 42° C for 22 
mins and then the culture was grown at 37° C for 4 hours. Cells were harvested 
by centrifugation at 5000 rpm for 10 mins.  Expression protocols were the same 
for WT, ΔE162 and W132F variants. 
1.2.2 Purification of Bs OxDc 
Cells were resuspended in lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 20 
mM imidazole, pH 8.5) and lysed with a high-pressure homogenization 
microfluidizer.  Cell debris was then separated by centrifugation at 25000 rpm for 
30 mins.  The protein was purified using a HisTrap HP column (GE Healthcare 
Lifescience).  The column was washed with buffer A (50 mM Tris-HCl, 500 mM 
NaCl, 20 mM imidazole pH 8.5) and protein eluted with buffer B (50 mM Tris-HCl, 
500 mM NaCl, 300 mM imidazole pH 8.5).  The protein was dialyzed overnight in 
storage buffer (50 mM Tris-HCl, 500 mM NaCl, pH 8.5) and further purified by gel 
filtration on a 360 mL S200 column equilibrated and eluted in storage buffer. The 
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protein eluted in fractions corresponding to a size of ~250,000 kDa, and these 
fractions were pooled.  The estimated yield was 40 mg/L of culture with a purity 
of ~95%. Purification protocols were the same for WT, ΔE162 and W132F 
variants. 
1.2.3  Crystallization of Bs OxDc 
1.2.3.1 High-throughput sparse matrix screens 
OxDc was concentrated to 5 mg/mL in storage buffer using an 
ultrafiltration centrifugal device with a molecular weight cutoff of 10,000 Da. High-
throughput screens from Hampton (Index, PEG Ion, Salt Rx, Grid Screen I & II, 
and Crystal Screen I & II) as well as the Midwest Center for Structural Genomics 
96-well screens 1-4 (Microlytic) were used to identify potential crystallization 
conditions for OxDc.    
1.2.3.2 Crystallization optimization  
Successful crystallization conditions for the W321F and ΔE162 variants 
were identified.  For W132F, crystals were obtained in 100 mM Tris-HCl, 2 M 
NaCl, 10% PEG 6000, pH 8.5 via hanging drop vapor diffusion at 17° C.  The 
ΔE162 crystallization conditions consisted of 100 mM CHES, 20% PEG 3000 pH 
9.5.  Rhombohedral crystals appeared in ~ 1 month and were approximately 0.01 
x 0.01 x 0.01 mm in dimension.  Crystals were cryoprotected by placing them in a 
solution containing 20% glucose in crystallization buffer and flash frozen in liquid 
nitrogen for data collection.  
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1.2.4 Data collection and processing 
All data were collected on the X25 beamline equipped with a Pilatus 6M 
detector of the National Synchrotron Light Source at Brookhaven National Labs.  
A full 360° data set was collected with 1° oscillations.  Data were processed 
using HKL200028.  
1.2.5 Model building and refinement 
Phasing was achieved via molecular replacement using WT OxDc in the 
open conformation (PDB 1UW8) as a search model in Phaser from the PHENIX 
software suite.29  Initial refinements were carried out using PHENIX Refine.30  
Manual refinement of residues and water molecules was performed using Coot 
graphical software.31 Final refinement statistics are shown in Table 1.2. 
1.3 Results and Discussion 
1.3.1 Crystal structure of ΔE162 
Several variants of the SENS loop with the cognate residues of Cs OxOx 
were generated to test the effects of these residues on the decarboxylation 
reaction of OxDc versus the oxidase activity of oxalate oxidase.  Efforts to obtain 
Wt OxDc crystals that diffracted were unsuccessful. However, crystals of the 
ΔE162 variant, in which Glu162 was deleted,were obtained. The ΔE162 variant 
was utilized to examine the dependence of the PCET reaction on Glu162 in 
OxDc as it is believed to be the primary amino acid responsible for proton 
transfer.  The goal in obtaining the crystal structure of ΔE162 and all SENS loop 
variants was to have structures of the OxDc variants to assist in understanding 
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the observed changes in reaction specificity.  In order to generate inactive 
enzyme to enable obtaining a substrate-liganded structure, Co(II) was substitute 
for Mn(II) upon induction of protein expression.  It has previously been shown 
that Co(II) significantly reduces the activity of OxDc32. The structure of the Co(II)- 
substituted variant with the catalytic Glu162 deleted (ΔE162) was solved to 2.6 
Å2. The data collection and refinement statistics are presented in Table 1.3. The 
protein was co-crystallized with 10 mM oxalate. Electron density near the active 
site was observed in a 2Fo-Fc map contoured at 3σ, consistent with the presence 
of oxalate. Overall, the ΔE162 structure is very similar to that of the WT closed 
structure (PDB ID 1UW8) with a RMSD of 0.23 Å.   
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Table 1.1: Data collection and refinement statistics for ΔE162 variant 
 
Data Collection Refinement 
    
Resolution (highest resolution shell) (Å) 24.78-2.60 (2.68-2.60) 
Protein residues/water molecules per asu 375/233 
X-ray Source X25, NSLS Other ligands per asu 3 
Wavelength (Å) 0.979 Reflections (work/free) 17122/17
12 
Space Group R32 Rwork/Rfree (%) 17.5/22.4 
Cell dimension (Å) a = b = 156.97, c = 121.95 Resolution (Å) 24.78-
2.60 
Reflections observed (unique) 896022 (17137) Average B-factor (Å2) 37.9 
Completeness (%) 98.9 (99.1) Protein (Å2) 35.2 
Rmerge (%)b 18.8(47.1) Co(II) (Å2) 37.2 
I/σ (I) 13.6 (2.4) Oxalate 40.9 
Redundancy 9.8(8.2) Water (Å2) 39.1 
  RMSD
c Bond lengths (Å) 0.008 
  RMSD Bond angles (
o) 1.05 
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The ΔE162 variant crystallized with oxalate bound in the active site. 
Comparison of the crystal structure of the ΔE162 variant to that of WT OxDc 
shows that the NTD metal center in the deletion variant does not change 
significantly and reveals the oxalate-binding mode for OxDc (Figure 1.6).    The 
only significant change in the metal-binding site is observed for His97.  Rather 
than coordinating the Co(II) metal through the ε2N the metal is centered between 
the ε2N and ε1C.   His97 makes two hydrogen-bonding interactions, one with a 
water molecule and the second with the substrate oxalate.  Therefore, it is 
possible that in this structure His97 is not making a true liganding interaction with 
the Co(II) ion.  This may be due to the presence of Co(II), which can be 5-
coordinate as opposed to Mn which is 6 coordinate. In this structure, one 
carboxylic acid group of oxalate occupies one of the water coordination sites on 
the metal.  The oxalate is held in place by both the metal ion as well as by 
forming a 3.5 Å hydrogen bond to Thr165 and a 3.7 Å hydrogen bond to Arg92. 
The pH profile for OxDC also indicates that the enzymes is most active at pH 4.2, 
which is around the second pKa value for oxalate (pKa1-1.17 pKa2=4.28). 
However, given that this is an X-ray crystal structure at 2.6 Å resolution it is not 
possible to determine the protonation states for the carboxylate groups of 
oxalate.  This structure confirms previous KIE which demonstrated that oxalate 
binds to the Mn(II) ion in an end-on fashion with one carboxylic acid group bound 
to the Mn(II) and the other positioned for decarboxylation22.  The KIE data show 
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that CO2 is produced from the end of oxalate that is protonated and it is most 
likely that the anion carboxylate portion of oxalate is bound to the metal.   
As indicated by the low rmsd compared to wild-type (0.23 Å2) most 
structural features of the protein do not undergo significant changes in the 
deletion variant.  However, the B-factors (61.3-68.8 Å2) residues 161-163 
compared to the average B-factor of the protein (35.2 Å2) as well as the poor 
density indicate that the SENS loop is very flexible and/or disordered in the 
absence of Glu162.   
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Figure 1.6: Active site of E162 (PDB ID 5HI0) A) Binding interactions of 
oxalate.  B) 2Fo-Fc electron density map of active site contoured at 1.0 σ.  
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Unfortunately, we have not been able to determine the structure of WT 
OxDc in the presence of oxalate.  This information is critical to determine if 
Glu162 is the proton donor involved in the second PCET step of the proposed 
mechanism of decarboxylation. However, the oxalate bound ΔE162 variant gives 
important insight regarding the positioning of Glu162.  As previously mentioned, 
the SENS loop adopts two conformations.  In the open form Glu162 is flipped out 
of the active site and in the closed form it is flipped in towards the metal ion 
(Figure 1.4).  A surface map of the open form of the enzyme (PDB ID 1J58) 
reveals a solvent channel that leads directly to the Mn(II) binding site (Figure 
1.6A). This solvent channel is not present in the closed form.  A voidoo analysis, 
which determines cavities within a crystal structure, of the open form reveals that 
the only possible binding site for oxalate is located within the Mn(II) binding site.  
This is shown as the black cage in Figure 1.6B.  We utilized our ligand-bound 
structure of ΔE162 to produce a model of oxalate binding to Wt OxDc in the 
closed form (Figure 1.6B) overlayed with the voidoo map of the open form. If 
Glu162 adopts the conformation seen in the closed structure of OxDc (Figure 
1.4B) then its position is too close to the Mn(II) metal (1.0 Å) to allow for oxalate 
binding.  Additionally, if Glu162 is in the open conformation where it is flipped out 
of the active site, it is not in position to transfer a proton.   
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Figure 1.7 A)Surface map of the open form of OxDc (1J58) showing solvent accessible channel to N-terminal Mn(II) 
(purple) binding site B) Voidoo map from the open form of OxDc overlayed with closed structure of OxDc (PDB ID 
1UW8). Oxalate (cyan) has been modeled into the active site based upon the ΔE162 structure 
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The overlap of Glu162 with oxalate raises a few possibilities as to the 
actual positioning of Glu162 in the catalytically competent form of the enzyme. 
First, it is possible that the absence of Glu162 in our OxDc construct allows for 
binding of oxalate in a conformation that is unlike that of the true Michaelis 
complex.  In the unliganded WT structure, the Mn(II) coordinates two water 
molecules.  While the liganded ΔE162 structure indicates that oxalate replaces 
one water molecule, it is possible that the presence of Glu162 would force the 
oxalate to occupy both water coordination sites on the metal by binding in a 
“side-on” orientation.  Figure 1.7 shows a model with oxalate binding in a side-on 
orientation where it occupies both water coordination sites.  This demonstrates 
that the closed conformation still positions Glu162 too close (2.3 Å) to the 
monoprotonated oxalate to represent the catalytically competent form of the 
enzyme.  A second possibility is that Glu162 adopts the conformation observed 
in the open structure and does not occupy the active site during catalysis.  This is 
unlikely given the mutagenesis studies that indicate Glu162 is vital for the 
decarboxylation reaction20,21,26.  Mutation of Glu162 to Ala or deletion of the 
residue abolishes decarboxylase activity19,23 while a conservative mutation, 
E162D results in only a ten-fold decrease in activity23.   More evidence for direct 
involvement of Glu162 in the second PCET step comes from the observation that 
mutation of E162 to Gln, which would still allow for decreased solvent access 
while not participating in proton transfer, is 50-fold less active than WT OxDc.  
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Therefore, it is necessary that at some point during catalysis Glu162 occupies 
the active site in a position for proton transfer  
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Figure 1.8: Model of oxalate binding to both water coordination sites of Mn(II) 
indicating that Glu162 in the closed conformation is still too close to represent 
the catalytically competent form of the enzyme 
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.  A third and most likely explanation is that Glu162 adopts different 
conformations at different stages in the reaction.   The T165V structure (PDB ID 
3S0M) has Glu162 in an alternate conformation where it neither occupies the 
open nor closed form (Figure 1.9A)21.  In this structure, carbonate is bound in the 
active-site and Glu162 is oriented up away from the bound ligand.  This altered 
conformation of Glu162 was attributed to the loss of T165 which forms a 
hydrogen bond with Glu162 in the closed form as well as steric interactions with 
the bound ligand precluding it from the active-site21.   However, it is possible that 
the T165V structure shows the positioning of Glu162 prior to decarboxylation of 
oxalate.  As with the closed form of WT OxDc, the T165V variant does not have a 
solvent channel leading to the active site21.   As our recent KIE data show that 
Glu162 is not directly involved in the steps leading to decarboxylation, Glu162 is 
not required to occupy the active-site prior to loss of CO2.  However, it was also 
shown to be critical for excluding solvent to protect the formyl radical anion as the 
less bulky chimeric variants showed increased production of H2O2 and a second 
CO2 molecule that were not formed from enzyme-catalyzed reactions27.  
Following decarboxyation, it is possible that Glu162 then drops down into the 
fully closed conformation to participate in the PCET step that results in formate 
production in OxDc.   Taken together the T165V variant may provide insight into 
the conformation of the SENS loop prior to decarboxylation, the closed form of 
the WT enzymes may indicate the positioning of Glu162 during protonation of the 
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formyl radical intermediate and the open WT structure may represent the position 
of the SENS loop for product release(Figure 1.9B)
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 Figure 1.9: A) Active site of T165 variant (PDB ID 3S0M) with carbonate bound. B) Schematic of Glu162 movement during various stages of catalysis. 
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1.3.2 Crystal structure of W132F variant 
To investigate the effect of second sphere residues on the active site 
metal a W132F variant of OxDc was generated. The structure of the Co(II)-
substituted W132F variant of Bs OxDc was solved to 2.1 Å. The data collection 
and refinement statistics of Co(II)-substituted W132F are reported in Table 1.2. 
The structure of the W132F variant is very similar to that of WT OxDc (PDB 
1UW8) with a RMSD of 0.26 Å. Figure 1.10 shows the superposition of the WT 
closed structure with that of the W132F structure.     
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Table 1.2: Data Collection and Refinement Statistics for the W132F Variant 
 
Data Collection Refinement 
    
Resolution (highest resolution shell) (Å) 47.39-2.095 (2.17-2.095) 
Protein residues/water molecules per 
asu 1508/1228 
X-ray Source X25, NSLS Other ligands per asu 8 
Wavelength (Å) 0.979 Reflections (work/free) 
91562/1997 
Space Group R32 Rwork/Rfree (%) 19.6/22.7 
Cell dimension (Å) a = b = 156.97, c = 
330.47 
Resolution (Å) 
49.06-2.09 
Reflections observed (unique) 177937 (91647) Average B-factor (Å2) 
 
Completeness (%) 99.7 (100) Protein (Å2) 23.15 
Rmerge (%)b 14.7 (29.2) Co(II) (Å2) 17.55 
I/σ (I) 3.3 (2.56) Water (Å2) 21.02 
Redundancy 19.1 (13.2) RMSDc Bond lengths (Å) 0.008 
  RMSD Bond angles (
o) 1.113 
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Figure 1.10: Overlay of WT Mn-bound structure (PDB ID 1UW8; green) with 
W132F Co(II)- bound structure (PDB ID 4MET; yellow).  Co(II) is colored 
red.  A) NTD metal-binding site of W132F overlayed with WT OxDc. B) CTD 
of W132F overlaid with WT OxDc. C) 2Fo-Fc electron density map of NTD 
metal-binding site of W132F variant contoured at 1 σ 
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Both the NTD and CTD metal-binding sites remain relatively unchanged 
compared to the WT structure as seen in Figure 1.10.  The primary difference 
between WT OxDc and the W132F variant is the loss of a hydrogen bond 
between Trp132 and E101 due to the mutation.  There is also a minor change in 
the conformation of His97 which adopts an edge-on conformation with the Co(II) 
metal positioned between ε 1C and ε2N rather than the ε2N of the side chain 
coordinating the Mn(II) metal as in the WT structure.  This was also observed in 
the Co(II) substituted ΔE162 structure, as previously mentioned.  The calculated 
EPR signal for the NTD with Mn(II) bound gave better agreement with the 
empirical EPR signal when the ε2N of His97 coordinating the metal with only a N 
atom was used.  This suggests that the observed change in binding of H97 to 
Co(II) is likely due to the presence of a 5-coordinate Co(II) metal center rather 
than a novel mode of His coordinating a metal center.   
Co(II) was substituted for Mn(II) in order to generate an inactive enzyme.  
The metal to ligand distances for the Co(II) and Mn(II) forms are shown in Figure 
1.11  All metal-to-ligand distances are similar within the error of the structure 
(0.23 Å coordinate error).  The metal-to-ligand distances were also cross-
checked via the Scripts Metalloprotein Database.  These metal-to-ligand 
distances for Mn(II) and Co(II) proteins were culled from a database provided by 
Dr. Mike Piza, The Scripps Research Institute originally created by gathering 
metal-liganded proteins from the PDB33.  The provided data were then curated to 
include only those metals with octahedral geometries with three histidine and one 
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glutamate contributing the metal binding residues.  Average values for each type 
of ligand and metal are shown in Table 1.3. Again, the metal to ligand distances 
observed in the Co(II)-substituted W132F structure were within range of those 
reported for previously published structures for Mn(II) indicating that the 
substitution of Co(II) for Mn(II) does not significantly alter the structure of the 
active site, providing a good model for the active form of the enzyme.  The only 
change observed is the decreased bond length for Glu162 to the water 
coordinated to Co(II).  It is likely that the increase in bond length is due to 
variability in how ordered the water molecule is and the exact geometry of the 
water ligand coordinated to the metal as it is modeled in the structure.  
 
Table 1.3: Average ligand-to-metal distances from Scripps Metalloprotein 
Database for Co(II) and Mn(II) 
Ligand Co(II) (Å) Mn(II) (Å) 
Glu 2.12 2.20 
His 2.12 2.26 
Water 2.24 2.29 
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Figure 1.11: Metal to ligand distances for Co(II) (black; PDB ID 4MET) and Mn(II) 
(pink; PDB ID 1UW8) containing OxDc structures 
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EPR signatures for each of the metal sites in the NTD and CTD have been 
previously assigned for the WT enzyme.34,35  The zero-splitting field (zfs) 
parameters, D and E are strongly dependent on the environment around the 
metal ion but are not limited to ligands that directly interact with the metal ion; 
therefore the differences in second sphere residues will alter the zfs signatures36.  
Given that the metal ligands for the NTD and CTD are identical, zfs values which 
are more sensitive to second sphere residues will be different for the NTD and 
CTD and provide more information about the electronic environment of the metal 
center. The EPR spectra and accurate zero-splitting field paramaters (zfs) for 
both the NTD and CTD meta-binding sites were distinguished based upon subtle 
changes in the specta at different pH values37.  These structural differences are 
also observed in both the closed (PDB ID 1UW8) and open (PDB ID 1J58) 
structures were the CTD Mn(II) has one or two waters bound, respectively.  Once 
the EPR signals for the NTD and CTD were deconvoluted, an OxDc mutant was 
utilized to generate an OxDc variant that perturbs the NTD EPR signal.  A 
significant change in the zero-field splitting paramaters for the NTD were 
observed in the W132F mutant.  The zero-field splitting D value for the NTD 
Mn(II) ion increased in magnitude from  -1350 to -1950 MHz.  As such, having 
the W132F structure is critical to interpreting factors that contribute to the 
observed changes in zfs values.  As shown through the crystal structure, the only 
change observed was the loss of the hydrogen bonding interaction between 
Trp132 and Glu101 and therefore the changes in zfs values were attributed to 
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the altered hydrogen bonding interaction between W132 and E101 which 
effected the electronics of the Mn(II) ion.  Ultimately, the experimental EPR data 
and W132F coordinates were utilized to assist in deriving computation methods 
for predicting EPR spectra.  A cluster model based upon the W132F structure 
was generated for MM/DFT calculations that should prove usefully for predicting 
and interpreting difficult, convoluted EPR spectra and serve as a future platform 
for both theoretically determining zfs values for other OxDc mutants as well as 
assisting in the analysis of empirical EPR data.   
 
1.4 Conclusions 
The crystal structure of ΔE162 provides the first picture of the Michaelis 
complex of OxDc.  The substrate oxalate binds in an “end-on” conformation as 
previously predicted by heavy isotope effect studies.22  Additionally, this structure 
calls into question the exact placement of the catalytic Glu162.  Future work 
should include attempts to obtain the crystal structure of the WT enzyme with 
oxalate bound to determine the location of Glu162 in the fully catalytically 
competent form of the enzyme. 
Oxalate decarboxylase exemplifies the difficulties in studying enzymes 
that utilize proton-coupled electron transfer steps.  The exact steps involved are 
often obscured by the finicky electronics of the active site.38  The crystal structure 
of the W132F variant illustrates how second-shell amino acids can affect the 
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electronics of the catalytic metal by simple removal of a hydrogen-bonding 
interaction with little change to the active site.39 
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Chapter 2: Bioinformatic Analysis of Cupin Superfamily 
With the wealth of genome sequences available, there is a great need for 
an informed way to annotate genes for protein structure and biological function. 
The cupin superfamily is perhaps the most functionally diverse superfamily given 
the diversity functions performed by its members.   This chapter describes the 
bioinformatic analysis of the cupin superfamily with the goals of relating protein 
sequence to structure/function with a focus to develop methods to exploit 
bioinformatics to predict function metal cofactors. 
2.1 Cupin superfamily background 
2.1.1 Cupin superfamily structure 
The cupin superfamily (CSF) is one of the most functionally diverse 
superfamilies and contains 64,578 members in the Pfam database40.  CSF 
members catalyze reactions ranging from decarboxylation to carbohydrate 
epimerization as well as acting as non-enzymatic seed storage proteins and 
transcription factors.41  
The name cupin is derived from “cupa”, the Latin term for barrel- a 
reference to the proteins’ beta barrel fold42  The cupin domain is composed of 
two motifs both comprising two beta strands separated by an intervening loop 
region of varying length (15-50 amino acids).43 Cupins can also exist as bicupins, 
which are comprised of two consecutive cupin domains, such as the proteins 
investigated in Ch 1 of this thesis.  The three-dimensional structure of the beta-
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barrel is conserved regardless of total protein structure as demonstrated in 
Figure 2.1 which shows selected members from the various metal (Mn(II), Zn(II) 
and Fe(II) or non metal) classes of CSF members.  
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Figure 2.1: Crystal structures of representative members of the CSF. A) Seed storage protein, beta-
conglycin (PDB ID 1UIJ) B) Non-metalloenzyme sugar isomerase dTDP-4-dehydrorhamnose 3,5-epimerase 
(PDB ID 3RYK) C) Mn(II)-binding oxalate decarboxylase (PDB ID 1UW8) D) Zn(II)-binding auxin-binding 
protein E) Zn(II)-binding mannose-6-phosphate isomers (PDB ID 1QWR) F) Fe(II)-binding isopenicillin N 
synthase (PDB ID 1ODM). Beta strands are shown in red, alpha helices in cyan and loops in magenta.  
Mn(II) ions are colored pink and Fe(II) are shown in yellow. 
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The quaternary structure of CSF members varies greatly. For example, 
cupins biological units can consist of monomers, dimers, trimers, tetramers and 
hexmers (Figure 2.2). The high thermal stability and resistance to proteases 
observed in this superfamily have been accredited to the strong inter-subunit 
packing interactions among these SF members.44,45  CSF members which 
perform similar functions such as the seed storage proteins (SSP) can either 
been trimers of bicupins or hexamers of bicupins indicating that function does not 
relate directly to the biological oligomeric assembly observed.   
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Figure 2.2: Representative structure of biological units from CSF.  Individual 
chains are colored differently.  Fe(II) ions are colored yellow and Zn(II) in grey. 
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2.1.2 Sequence conservation in the cupin superfamily  
The cupin superfamily contains two consensus sequence motifs within the 
beta barrel.  Motif 1 has the general sequence G(x)5HxHx3,4E(x)6G and Motif 2 
G(x)5PxG(x)2H(x)3N.44 Amongst the metal binding cupins, the two His residues in 
Motif 1 and one His in Motif 2 are primarily responsible for metal chelation.  As 
more cupin proteins have been identified it has become clear that there is great 
variation in this motif.  For example in non-metal binding CSF members the metal 
binding HxH motif has been lost.  In Figure 2.3 the location of the conserved 
sequence motifs are mapped onto OxOx (PDB ID 2ETE).  Outside of these two 
motifs, the sequence conservation amongst divergent memebers of the CSF is 
fairly low (~15%).  The low overall sequence conservation gives rise to the 
diverse functions utilized within the similar protein scaffold.  
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Figure 2.1: Conserved sequence motifs within the CSF (red) mapped onto 
the structure of OxOx (PDB ID 2ETE) 
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2.1.3  Metal binding in cupin superfamily 
Several enzyme classes within the CSF bind metals within the beta barrel 
of the cupin fold16,41,44,46.  Cupins have been reported to bind several different 
metals including Fe(II), Zn(II), Cu(II), Mn(II) and Ni(II), Co(II).17,41,44,47 Significant 
biochemical data have been provided to support the use of Fe(II), Zn(II) and 
Mn(II) in catalysis while proper biological annotation remains to be determined for 
the Ni(II)- and Cu(II)-annotated proteins.  The metal coordination motifs for the 
Fe(II), Mn(II) and Zn(II) proteins varies although throughout the CSF His and Glu 
residues are the most common liganding-residues (Figure 2.3) 
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Figure 2.2: Metal-binding sites of representative members of the cupin 
superfamily. A) Mn(II) (purple) binding site of OxDc (PDB ID 1UW8) B) 
Fe(II) (red) binding site of proline hydroxylase (PDB ID 1E5S) C) Zn(II) 
(yellow) binding site of Ma ChrR (PDB ID 3O14).  Water ligands are 
shown as small red spheres  
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A question remains to be answered for any metal binding SF- given such 
conserved structure, how do enzyme discriminate amongst the various 
bioavailable metals in order to perform the correct catalysis? It is known that 
many enzymes are capable of binding various metal while also being able to 
perform catalysis (although the resultant reactions may be considered off-
pathway)32,48,49.  Possibly the most well studied case of mismetallation is 
ribonucleotide reductase.50 It was observed that in in vitro studies of eukaroyotic 
RNR, Mn(II) can compete with Fe(II) binding which leads to reduced ability to 
generate dNTPS.51  
Within the CSF, the ability to bind several metals and perform catalysis 
has been observed for several members.  The catalyzed reaction may be similar 
while the activity of the enzyme is reduced as in mismetallation of OxDc32,48,49 or 
the mismetallation may result in a different product52. The previously mentioned 
acireductone dioxygenase has been found to bind Fe(II) and Ni(II) in vitro.52  The 
Fe(II) form of the enzyme catalyzes the on-pathway reaction penultimate step in 
the methionine salvage pathway that results in the formation of formate and the 
ketoacid precursor of methionine, while the Ni(II) form catalyzes an off pathway 
reaction that results in formation of formate, carbon monoxide, and 5-(thiomethyl) 
propionate.  Other members of the CFS are known to utilize the same metal ion 
for different functions.  The Mn(II)-binding enzymes contain members that 
catalyze oxalate oxidation6,7 and decarboxylation53 as well as D-lyxose 
isomerization.54 Zn(II)-dependent protein can function as transcription factors55–
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57, auxin-binding58, and sugar isomerase enzymes59–64. Given the diverse 
sequences within this superfamily, prediction of function and metal utilization 
remains difficult.   
Recently an attempt at relating protein structure and sequence with metal 
dependence and function in the CSF using protein similarity networks has been 
reported.17  In this work, Uberto et. al. mined the PDB for CSF members and 
redundant sequences were removed to generate a data set that included 183 
structures.  Sequence similarity and structure similarity networks were then 
generated and annotated by metal type to show how the proteins cluster based 
upon metal incorporation.  In this analysis, specific clustering of metals was not 
observed leading the authors to conclude that metal incorporation does not 
depend on sequence or structure based determinants.  However, the data set 
was not curated for proper annotation of metal utilization, thus resulting in the 
overlap of various metals within clusters as well as non-biologically relevant 
metals such as Cd(II) being assigned to a protein.  Additionally, the small number 
of proteins used to generate the network limits the extension of this network to all 
members of the CSF.   
In the current work, a set of proteins from the PDB was assembled using 
only structurally and functionally well-characterized proteins to generate a “gold 
standard set” (GSS) of known proteins.  A sequence similarity network was 
generated from all CSF members from the Pfam database which contains 64,578 
sequences from 2066 species.  The GSS proteins were then mapped onto the 
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SSN to visualize how the proteins cluster with metal incorporation.  The goal of 
this work was to provide a method for predicting function and metal dependence 
of uncharacterized proteins from the cupin clan.  
2.2 Materials and methods 
2.2.1 Curation of the Cupin “Gold Standard” Set 
Investigation of the data set utilized in the Uberto and Moomaw paper 
revealed significant improper assignment of metal utilization in the 183 PDB 
structures utilized in the structure-based sequence alignment. This was due to 
the strict use of the metals present in the PDB file, a number of which were not 
the biologically relevant metals. Therefore, this data set was hand-curated by 
using the PDB structure, uniprot classification and literature to eliminate any 
proteins which had been improperly assigned.  It is possible that some CSF 
members utilize Cu(II) or Ni(II) but sufficient biophysical data could not be found 
in the literature to support including Cu(II) or Ni(II)-bound structures in the GSS. 
The final data set contains 83 PDB structures which either utilize no metal, Fe(II), 
Mn(II), and Zn(II).   The cupin gold standard set is located in Appendix II.   
2.2.2 Generation of Cupin Superfamily Sequence Similarity network  
A sequence-based similarity network was generated by Mr. Linqi Luo in 
the Allen laboratory using the Enzyme Function Initiative Enzyme Similarity Tool 
(REF).  An all-by-all BLAST search was performed for the cupin pfam clad 
(CL0029).  To allow visualization of this large family, representatives nodes were 
generated which comprise a set of sequences that share a sequence similarity of 
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≥55%.  The full representative network contains 33,866 nodes and 24,349 edges.  
The representative meta-node network was visualized using Cytoscape.65 
2.2.3 Sequence alignments and figure generation 
Structure-based sequence alignments were generated using the Espresso 
server66.  Figures for sequence alignments were generated using Espript67  
Structural overlays were performed using Coot31 and final protein structures were 
rendered in PyMol68.  
2.3 Results and discussion 
2.3.1 Sequence similarity network 
A sequence similarity network was generated for the cupin pfam clan 
(Figure 2.5).. The large colored boxes indicate nodes which contain proteins from 
the GSS and are colored according to the metal (or no metal) the protein binds.  
As can be seen, some clusters contain multiple proteins from the GSS.  
However, unlike the result observed previously17, when two or more proteins 
from the GSS are found within the same cluster, they contain the same metal 
specificity.   Notably, the previous work utilized an e-value of -3.5 which allows 
for less stringency in similarity when assigning a sequence to a node yet 
significant overlap was observed.   The lack of metal overlap in our more 
stringent network (e-value = -20) is likely due to the more stringent cutoff and the 
curation of the GSS of known structures to remove improperly assigned metal 
ions.  As this network contains all known members of the cupin clan, useful 
information can be generated from this SSN.   
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Figure 2.3: Sequence similarity network for cupin superfamily displayed at an e-value of -20.  Representative 
nodes containing proteins in the gold standard set are indicated by boxes colored by metal ion. Fe(II) is magenta, 
Mn(II) is green, Zn(II) is yellow and proteins without metals are black. Circled areas show where multiple metals of 
the same type are found in the same cluster 
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2.3.2 Seed storage proteins and non-metalloenzymes 
The CSF contains two subfamilies that do not bind any metal ions, seed 
storage proteins and non-metalloenzymes (black, Figure 2.5) These two groups 
of proteins are enlarged in Figure 2.6 and colored by domain of life (archea, 
bacteria, eukaria).   Review of the literature of these proteins in the gold standard 
set reveals that these non-metalloenzymes in the cupin superfamily function as 
sugar isomerases.69–76 The sugar epimerase enzymes are exclusively from 
prokaryotes with no members from eukaryotic species. The bacterial sugar 
epimerase enzymes are involved in cell wall synthesis.69–75,77 The SSP cluster 
contains primarily plant eukaryotes. The SSP function primarily as reserves of 
amino acids for seeds during desiccation .41   
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 Figure 2.4: Clusters containing non-metalloenzymes and seed storage 
proteins from GSS.  Prokaryotes are colored green and eukaryotes are 
shown in red 
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2.3.2.1 Sugar epimerase enzymes 
The sugar epimerase enzymes from the GSS fall within a cluster that is 
separate from that of the seed storage proteins (Figure 2.6) Of the known 
structures of prokaryotic sugar epimerases in the SSN all are monocupins which 
form dimers.  The structure-based sequence alignment (Appendix IV) of the 11 
sugar epimerases in the GSS shows a number of similar residues which 
distribute mostly over the beta sheet region as shown mapped onto the structure 
of RmlC (PDB ID 1NYW) (Figure 2.7). The 11sugar epimerases have 34.5% 
sequence similarity and 4% sequence identity.  To assess how sequence 
similarity is related to function, the conserved and similar residues were mapped 
onto the structure of a complex dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase 
with substrate analog dTDP-D-glucose (Figure 2.8). The primary area of 
concentration of conserved residues is located on the end of the beta barrel 
(strand 2) which corresponds to motif 2 that was used to define the CSF (Figure 
2.3). There are also areas containing conserved residues within the beta barrel 
as well as in the α-helices that flank the opening to the beta barrel.  These areas 
of conservation may provide insights into the conserved catalytic core of the 
sugar epimerases.   
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Figure 2.5: Mapping of conserved (red) and similar (yellow) residues from sugar epimerase enzymes onto PDB ID 
1NYW 
 
 
 
    
 
59 
The structure-based sequence alignment mapped onto the structure of 
dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase allows for prediction of the 
active-site of these enzymes.  Figure 2.8 shows the liganded structure of dTDP-
6-deoxy-D-xylo-4-hexulose 3,5-epimerase (PDB ID INYW) with conserved and 
similar residues in complex with a substrate analog, dTDP-6-deoxy-D-glucose.  
The substrate-binding residues are very similar within the sugar epimerases with 
the exception of Glu78 in dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase which 
interacts with a hydroxyl group of the sugar portion of the substrate.  The identity 
of this residue varies within the sugar epimerase enzymes and is possibly 
involved in substrate specificity.  Additionally, the areas of moderate conservation 
on the α-helix (helix 2) that flanks the beta barrel is involved in coordinating the 
phosphate group of the dTDP moiety of the substrates.  His76 is completely 
conserved within these selected enzymes and is proposed to be the active site 
base. 75                 
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 not surprising given that these enzymes bind similar substrate-dTDP-sugars, although the exact sugar and 
chemical reaction vary.   
 
Figure 2.6:A) Liganded structure of dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase (PDB ID 1NYW) colored with 
conserved residues colored as in Figure 2.7 and with substrate analog dTDP-D-glucose shown as sticks (cyan) B) 
Active site of dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase showing interactions with substrate analog dTDP-D-
glucose.  Residues are numbered according to PDB ID 1NYW  
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 Overlay of the liganded structures (INYW, 3RYK and 1EPZ) of the 
sugar epimerases shows strict conservation of the active site.  This is not 
surprising given the areas of conserved residues (Figure 2.8) as well as the 
similarity of substrates.  Figure 2.9 shows a superimposition of three liganded 
sugar epimerase enzymes with substrate analogs bound.  In all cases, the 
thymine portion of the substrate is bound in the same location within the beta 
barrel of the cupin fold and the phosphate portion of the deoxyribose 5’-
diphosphate interacts with the conserved flanking helix.  The CSF non-metal 
sugar epimerase enzymes show the high structural similarity and conservation of 
the active site location.   
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Overlay of the liganded structures of various sugar epimerase enzymes show strict conservation of the 
active site (Figure 2.10).  This is not surprising given the similarity in substrates, the location of conserved      
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Structural overlays of various Rmlc sugar epimerase enzymes showing the conserved location of the 
substrate binding site. Ss dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase (PDB ID INYW) (blue) with dTDP-D-glucose 
(cyan), Ba dTDP-4-dehydrorhamnose 3,5-epimerase (3RYK) (green) with dTDP (yellow) and Mt dTDP-6-deoxy-D-xylo4-
hexulose 3,5-epimerase (orange) (PDB 1EPZ) with dTDP (purple) 
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2.3.2.2 Seed storage proteins 
The SPP cluster contains two distinct subclusters which separate based 
upon the class of SSP (Figure 2.6).  The two classes of cupin SSP are divided 
based upon their sedimentation coefficients and termed 11S and 7S. Both the 
11S and 7S SSP are bicupins.  The 7S SSP subunits are slightly smaller ~420 aa 
and the 11S SSP subunits are larger ~490 aa, The 7S SSP oligomerize into 
trimers (Figure 2.11A) and the 11S SSP form homohexamers (Figure 2.11B).   
The trimers are formed by interlocking alpha helicies that flank the cupin beta 
barrel.  The homohexamers for by two faces of trimers interacting.   Similar trimer 
and hexamer interactions are formed within several members of this family 
including OxDx which forms a homotrimer and OxDc that forms a 
homohexamter. 
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 Figure 2.9: A) Homotrimer biological of the 7S SSP and B) homohexamer 
biological unit of the 11S SSP 
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Structure-based sequence alignments of the 11 SSP in the GSS show 
fairly low conservation (3.8% identity and 27.1% similarity) (Appendix V).  
However, when broken down by 7S and 11S groups, there is a high level of 
sequence conservation (18.7% identity and 41.0% similarity for 11S SSP 
(Appendix VI) and 7.2% identity and 42.2% similarity for 7S SSP (Appendix VII)).  
Figure 2.12 shows the mapping of conserved residues onto representative 
structures of the 7S (PDB ID 1UIK) and 11S (PDB ID 1OD5) SSP. This 
subclustering suggests that at this level of stringency it is possible to determine if 
a protein is a 11S or 7S seed storage protein.  The residues involved in forming 
the trimer interactions are conserved in the 7S proteins as well as the 11S 
proteins.  The residues that form the dimer of trimers in the 11S SSP are 
conserved as well. 
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 Figure 2.10: A) Sequence conservation of 7S seed storage proteins (PDB ID 1UIK)  B) Sequence conservation of 
11S seed storage proteins (PDB ID 1ODS).  Yellow indicates similar residues while red indicates completely 
conserved residues 
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2.3.3 Mn(II)-binding proteins 
The four proteins from GSS that contain Mn(II) appear in three clusters in 
Figure 2.5 suggesting low sequence similarity amongst these enzymes.  
Structure-based sequence alignments of the Mn(II)-containing proteins reveal an 
overall poor conservation of sequence (Appendix VII) between proteins in 
different clusters.  Two proteins from the GSS lie within the same cluster and 
have been shown to have oxalate decarboxylase activity.23,49,78  This cluster 
contains bacteria and plant eukaryotes  which is consistent with what is known 
about OxDc.13  The second cluster containing a Mn(II)-dependent protein from 
the GSS includes oxalate oxidase.  OxOx is a well characterized Mn(II)-
dependent protein which converts oxalate to two CO2 and H2O2.7,11,45,79  Oxalate 
oxidase is suspected to play a role in fungi and plants as a defense mechanism 
against this cluster contains only eukaryotic fungi and plant members.  The final 
cluster containing a Mn(II)-dependent enzyme from the GSS includes a novel 
sugar isomerase from a pathogenic E. coli strain, O157:H7 a 
enterohaemorrhagic bacteria80.  Most of these proteins are from bacteria with 
one member from archea. This sugar isomerase protein from the GSS has been 
shown to have isomerase activity in a Mn(II)-dependent fashion with specificity 
for D-lyxose.81  This node does not contain many members with 27 proteins in 
total.  This may be due to the fact that very few bacterial species utilize D-lyxose, 
which is utilized in cell wall synthesis.82,83 The appearance of the four Mn(II)-
dependent enzymes within three distinct clusters is reflective of their low 
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sequence similarity and gives rise to the different functions of these enzymes 
which utilize the same protein fold and metal ion.  
Since only one Mn(II) cluster contains more than one protein of known 
structure it is the only cluster from which direct comparison of structure may be 
made.  One of the proteins within this cluster is Bs OxDc- discussed in Chapter 
1.  The second, MncA from Synechocystis sp has been shown to have OxDc 
activity.49  Sequence alignments of Bs OxDc and MncA reveal a high level of 
sequence conservation (42% identity, 12,2% similarity) (Appendix IV).  A 
mapping of sequence conservation onto the structure of MncA (PDB ID 2VQA) is 
shown in Figure 2.11.  The primary areas of conservation are located within the 
beta barrel.  The Mn-coordinating residues are strictly conserved in both the NTD 
and CTD.  Additionally, MncA contains a glutamate residue (Glu170) proposed to 
be important for catalysis due to its positioning in a loop that is located near the 
active site similar to that of the SENS loop in Bs OxDc49.  Rather than a 
conserved SENS sequence as in the Bs ortholog, MncA has a SEGA loop in the 
same location.  However, strict conservation of the SENS loop is not required for 
OxDc activity.19,21–23,84  Initial reports of Bs OxDc predicted the CTD to the be the 
catalytic domain due to the presence of Glu333 in the loop corresponding to the 
SENS loop, which could act as a proton shuttle.78  In MncA, the residue 
corresponding to Glu333 is an alanine, indicating that the likely active site is also 
only in the NTD.49  Thus we propose that in MncA as in Bs OxDc, the NTD alone 
bears the active site. The cluster containing the OxDc proteins is expanded in 
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Figure 2.11B.  The nodes are colored according to species domain.  The cluster 
containing OxDc and MncA comprises proteins that are found in both 
prokaryotes and eukaryotic fungi.  OxDc is known to be found in both bacteria 
and fungi and it is likely that this cluster represents OxDc orthologs.  
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Figure 2.11: A) Conservation mapping of Mn(II)-dependent oxalate decarboxylases onto the structure of 
MncA (PDB ID 2VQA).  Conserved residues are red and similar residues are yellow. Black box shows 
location of SENS loop in Bs OxDc B) Cluster containing OxDc and MncA colored by domain.  Prokaryotes 
are green and eukaryotes are red  
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2.3.3.1 Comparison of Mn(II) binding proteins 
Figure 2.12 shows structural overlays of OxDc (PDB ID 1UW8), OxOx 
(PDB ID 2ETE) and the lyxose sugar isomerase (LI) (PDB ID 3MPB).  While 
OxOx are monocupins, they are shown as dimers (as they occurred in the crystal 
lattice) in this depiction to demonstrate the structural similarity between these 
three Mn(II)-dependent enzymes.  Overall, the structures of these enzymes are 
very conserved with the exception that LI lacks the alpha-helical claws in OxDc 
and OxOx (residues 168-177 and 344-371 using OxDc numbering) which are 
involved in trimer interactions and contains an additional alpha helix that runs 
across the end of the cupin barrel.   
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Figure 2.12: Structural overlays of Mn(II) dependent enzymes from GSS. OxOx (PDB 1ETE; blue), LI(PDB ID 
3MPB; green), OxDc(PBD 1UW8; red) 
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 The metal-binding motif of the three enzymes is the same (Figure 
2.13).  All three of these Mn(II) dependent enzymes utilize a 3His 1Glu metal-
binding motif.  There are substrate-bound structures available for OxDc (PDB ID 
5HI0) and LI (PDB ID 3MPB).  As can be seen in Figure 2.13, both OxDc and LI 
coordinate their substrate in the same coordination site on the Mn(II) ion.  This 
suggests that the Mn(II)-dependent cupins have evolved to utilize the same 
structural scaffolds for very different chemistry (ie decarboxylation versus 
isomerization).   
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 Figure 2.13: Overlays of Mn(II) dependent active sites. LI is shown in blue (PDB 
ID 3MPB) with substrate analog fructose in cyan.  OxOx (2ETE) is shown in 
green and OxDc (5HI0) is shown in blue with substrate oxalate shown in 
orange.  
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 Studies of LI orthologs show a catalytic dependence for Mn(II) 81,82.  
Kinetic studies of binding-site variants reveal that catalytic activity is completely 
abolished with the mutation of D186 to Ala.  Notably, this Asp residue occupies 
the same position in the active site as the proposed catalytic Glu162 from OxDc 
(Figure 2.14) and is oriented towards the sugar C3 hydroxyl group of fructose, 
which would structurally correspond to the C3 sugar of D-lyxose where 
isomerization to D-xylulose occurs.  Given the conserved positioning, catalytic 
dependence and the need for an active site acid/base for the isomerization 
reaction we hypothesize that E186 is the primary catalytic residue in these LI.  
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Figure 2.114: Active site of LI (PDB ID 3MPB) with fructose bound. 
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2.3.4  Zn(II)-binding cupin proteins 
As can be seen in Figure 2.5, the Zn(II)-binding proteins from the GSS are 
found in 7 different clusters at an e-value of -20.  This is not surprising given the 
disparate functions supported by these proteins. The functions of the Zn(II)-
binding cupins include sugar isomerases, sigma (σ) factors, transcription factors, 
and an auxin-binding protein.   
2.3.4.1 Zn(II)-dependent transcription factors  
The Zn(II)-dependent transcription factors require Zn(II) in order to bind 
the σ-factors necessary for their function in the suppression of RNA translation.55 
The GSS contains three proteins which are classified as transcription factors.  
Notably, each of these three transcription factors are found in a different cluster 
(Figure 2.15) within the SSN (Figure 2.5).  One cluster contains the protein ChrR 
from Rhodobacter sphaeroides, a species of purple bacteria.  A second cluster 
contains ChrR from Marinobacter aquaeoli, a deep sea dwelling extremophile 
bacteria.  This cluster also contains two eukaryotic members, both of which are 
types of algae.  The third cluster contains a transcription factor from Vibrio 
cholera.  This cluster primarily contains bacterial transcription factors as well as 
few from fungi (eukaryote) and archaea sequences.  Overall, the Zn(II)-binding 
cupin transcription factors are found in prokaryotic species suggesting that this 
subclass of the cupin fold is not utilized for this function in higher order species. 
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Figure 2.15 Clusters containing Zn(II)-binding proteins from GSS colored by domain.  Green indicates 
prokaryotes, red eukaryotes, blue archaea and white is unclassified.  A) Cluster containing PDB ID 
2Z2S B) Cluster containing PDB ID 1Y9Q C) Cluster containing 3O14 
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The sequence alignment for the three Zn(II)-binding transcription factors 
reveals a low level of similarity (3.2% identity, 8.1% similarity; Appendix X).  
Figure 2.16 shows the structures of the three Zn(II)-binding transcription factors 
from the GSS.  The overall structures are very different and the positions on the 
scaffold from which the metal binding residues originate also differ dramatically.  
The Rs ChrR and Ma ChrR both utilize a HxHx(3,4)E binding motif with an 
additional His ligand located downstream in the primary sequence (20-24 aa 
away; HxHx(3,4)Ex(24)H ).  The Vc transcription factor utilizes a (Hx(5)Ex(34)HxY 
motif for the four metal-binding ligands.  
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 Figure 2.16  A-C Structure of Zn(II)-dependent transcription factors  A) Rs ChrR (PDB ID 2Z2S) B) Ma ChrR 
(PDB ID 3O14) C) Vc transcription factor (PDB ID 1Y9Q). D-F) Metal-binding sites of Zn(II)-binding transcription 
factors D) RsChrR E) Ma ChrR F) Vc transcription factor with methionine bound in pink 
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While all three Zn(II) transcription factors from the gold standard set vary 
greatly in their overall structure, when comparing the metal binding sites within 
the cupin barrel it becomes clear that although the Rs Ma ChrR and Vc 
transcription factors utilize the same location within the cupin fold to coordinate 
Zn(II) (Figure 2.17).   
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Figure 2.17) Overlay of the cupin domains of the three Zn(II)-dependent 
transcription factors with available structures.  Rs ChrR (PDB ID 2Z2S; 
orange), Ma ChrR (PDB ID 3O14; green) and Vc transcription factor (PDB ID 
1Y9Q; red)  
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2.3.4.2 Zn(II)-binding auxin-binding protein 
Auxin is a plant hormone that regulates elongation, division, differentiation 
and morphogenesis.85  The cluster containing auxin-binding protein from the 
GSS contains two distinct sub-clusters, one containing eukaryotic species and 
the other prokaryotic species (Figure 2.18). The PDB contains one unique 
structure of an auxin-binding protein in complex with Zn(II) and auxin (PDB ID 
1LRH) (Figure 2.19).  The Zn(II) is liganded by a HxHx3E motif with the fourth 
ligand contributed by a His residue positioned 43 residues downstream.  The 
auxin is coordinated to the Zn(II) through the carboxylic acid group and the 
napthyl ring lies in a hydrophobic pocket.86 
 
 
 
 
 
 
 
 
 
Figure 2.18) Cluster containing auxin-binding protein (PDB ID 
1LRH) colored by domain.  Green indicates prokaryotes and 
red eukaryotes 
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Figure 2.19: A) Crystal structure of ABP in complex with auxin (PDB ID 1LRH). B) Zn(II)-binding site of ABP with 
auxin bound.  Residues are numbered according to PDB ID 1LRH 
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2.3.4.3 Zn(II)-binding sugar isomerase enzymes 
The GSS contains four cupin proteins annotated as Zn(II)-dependent 
sugar isomerase enzymes.  Three of the four are annotated as type 1 mannose-
6-phosphate isomerases (PMI) and the fourth as 4-deoxy-L-threo-5-hexosulose-
uronate ketol-isomerases. 
Structure-based sequence alignments of the four sugar isomerase 
enzymes reveals little similarity with 12.5% identity and 13.2% similarity 
(Appendix XI).  The SSN shows that the four sugar isomerase enzymes appear 
in three distinct clusters.  One cluster contains MPI from Bacillus subtilis (PDB ID 
1QWR).  The cluster contains primarily anaerobic bacteria (although Bs is an 
obligate aerobe), and a few eukaryotic fish parasites.    Bs MPI is a bicupin 
(Figure 2.20A) and crystallized as a dimer however the biological unit is 
unknown.  The Zn(II) is coordinated in the NTD by three protein residues- His98, 
His173, and Glu116 (Figure 20B).  No Zn(II) is bound in the CTD in the X-ray 
crystal structure and the corresponding ligating residues (HxHx5E) are not 
present.  Both the NTD and CTD contain one sulfate molecule.  The sulfate 
molecule in the NTD is located 7 Å away from the Zn(II) ion.  This could 
correspond to the phosphate binding location of the mannose-6-phosphate 
substrate, although no liganded structures are available to verify this.  The sulfate 
is coordinated by four protein residues (Lys15, Lys96, Arg207 and Ser94).   
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Figure 2.20: A) Crystal structure of Bs PMI (PDB 1QWR). B) Zn(II) and sulfate binding site.  Residues are 
numbered according to PDB 1QWR 
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The second cluster that includes a Zn(II)-binding protein from the GSS 
contains 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase (KduI) from E. 
coli.  This cluster contains primarily bacterial proteins.  KduI is involved in the 
pathway that breaks down pectin to pyruvate in soil bacteria.87  KduI converts 5-
keto-4-deoxyuronate to 2,5-diketo-3-dexoygluconate.  KduI (Figure 2.21) 
coordinates Zn(II) via an HxHx4E motif with a third histidine residues down 
stream in the sequence. To date there are no enzymatic studies to show the 
dependence of the enzyme on Zn(II) and it is therefore possible that it utilizes 
another metal for the isomerase reaction, or none at all.  However, given the 
positioning of the metal-binding residues and the nearby phosphate in the 
structure it is likely that this is a Zn(II)-utilizing sugar isomerase.     
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Figure 2.21 Crystal structure of KduI (PDB 1XRU) with Zn(II) and a PEG molecule bound. B) Zn(II) 
metal-binding residues.  Residues are numbered according to PDB 1XRU 
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The third cluster of Zn(II)-binding sugar isomerase enzymes contains two 
phosphomannose isomerases (PMIs).  The sequence alignment for the two can 
be seen in Appendix XII.  The two share 29.3% sequence identity and 16.3% 
similarity and good structural similarity 1.85 Å RMSD (Figure 2.22A). Additionally, 
mapping of conserved and similar residues onto PDB 3H1Y reveals conservation 
in the site where product fructose-6-phosphate (F6P) bound in 2H1Y (Figure 
2.22B).  There is strong conservation of residues in the NTD cupin fold and the 
loop surrounding the F6P.  The flanking alpha helices also show strong 
sequence conservation but their function is not known.  These two PMIs clearly 
show strong conservation of structure and Zn(II)-binding location and residues 
indicating that they share a common ancestor.  
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Figure 2.22: A) Structural overlays of Type 1 PMIs from Salmonella enterica (PDB ID 3H1Y; blue) and Candida 
albicans (PDB ID 1PMI; magenta). B) Conserved (red) and similar (yellow) mapped onto PDB ID 3H1Y with 
product F6P bound. 
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Notably these PMIs bind their substrate on the opposite face of the metal 
as compared to that of OxDc and LI.  The F6P makes no interaction with the 
Zn(II) ion and is located 5 Å away (Figure 2.23).   Kinetic data support Lys132 as 
the catalytic residue suggesting that this may be the true binding location of 
F6P.60,61  As this is a different substrate binding location as previously seen in the 
liganded structures this may suggest that the cupin fold allows for variation in 
substrate binding mode and location while maintaining the same overall fold.   
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Figure 2.23: Zn(II)-binding site of PMIs from GSS (PDB ID 1HM1; 
cyan; 1PMI; magenta) with F6P (blue) and Zn(II) (yellow) bound 
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2.3.5 Summary of Zn(II)-binding proteins 
The Zn(II) proteins show the greatest variation in function, structure, and 
metal binding when compared to the non-metal-binding cupins and the Mn(II) 
cupins. Overlay of the Zn(II)-binding transcription factors, auxin-binding protein, 
and sugar isomerase enzymes reveals that while the location in protein 
sequence of the liganding residues varies, the location of the coordinating side 
chains of the liganding residues within the cupin fold is conserved (Figure 2.24).  
More representatives are required to determine further sequence determinants 
for Zn(II) incorporation and protein function which likely come from sequence 
motifs located outside of the metal-binding site.   
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Figure 2.24: Structural overlays of cupin beta barrel of Zn(II)-dependent 
proteins.  Liganding residues are colored by the location in which they cluster. 
      
 
95 
 
2.3.6 Comparison of cupin superfamily members 
The characteristic motifs of the CSF- G(x)5HxHx3,4E(x)6G and 
G(x)5PxG(x)2H(x)3N is lost in many members of the CSF with the exception of the 
Mn(II) dependent enzymes.  All the Mn(II)-dependent enzymes utilize a 3His 
1Glu motif for binding the metal ion.  Of the Zn(II)-binding proteins only the ChrR 
transcription factors, KduI (sugar isomerase) and ABP utilize HxHx3-4E metal-
binding ligands motif.  However, the location of the liganding residues is 
preserved within the cupin fold regardless of liganding residue position in the 
protein sequence.   
Not surprisingly, the non-metal cupins have lost the metal binding 
residues.  However, comparison of the active sites of the non-metal sugar 
epimerase enzymes with that of OxDc (a representative member of the Mn(II) 
enzymes), it becomes clear that the location of the active sites has been 
maintained (Figure 2.25) in the currently available structures. 
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Figure 2.25: A) Structural overlay of non-metal utilizing dTDP-4-dehydrorhamnose 3,5-epimerase (PBD 1NYW; 
magenta) with the NTD of OxDc (PDB ID 5HI0; blue) B) Mn(II) (purple) and substrate binding sites of OxDc and dTDP-
4-dehydrorhamnose 3,5-epimerase.  Oxalate is colored light blue and d-TDP-D-glucose (cyan) 
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This conservation of binding site is also observed when comparing the 
liganded OxDc structure (PDB 5HI0) with the liganded Zn(II)-utilizing ABP 
structure (1LRH) (Figure 2.26).  Again both the Zn(II) and Mn(II) metal binding 
sites are located in the same place within the cupin beta barrel and the ligands, 
oxalate or auxin, are bound on the same face of the metal and the same 
coordination sites are used on the metal for substrate binding.  
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Figure 2.26: A) Structural overlay of Zn(II) utilizing ABP (PDB ID 1LRH; green) with OxDc (PDB ID 5HI0; blue) 
B) Metal-binding sites for ABP with Zn(II) (yellow) and auxin (red) and the NTD of OxDC with Mn(II) pink and 
oxalate (teal) 
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However, not all ligand-binding sites in the CSF are conserved.  The 
overlay of the Zn(II)-dependent Type 1 PMI from the CSF with that of model 
cupin OxDc show that while the metal-binding sites within the cupin fold of the 
Zn(II) and Mn(II) are conserved, the ligand-binding sites are not located in the 
same location in the cupin beta barrel (Figure 2.27).    
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Figure 2.27: A) Structural overlay of Zn(II)-dependent PMI (PDB 3H1Y; cyan) with OxDc (PDB ID 5HI0; blue). B) 
Metal and ligand binding sites of PMI with Zn(II) (yellow) and F6P (red) and OxDc with Mn(II) (purple) and 
oxalate (teal). 
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 As described above the location of the metal and ligand-binding sites in 
the CSF are conserved.  Topology maps of the SSP, non-metal-dependent sugar 
isomerases, Mn(II)-dependent enzymes and the Zn(II)-binding transcription 
factors (Appendix XIII) show that the majority of the alpha-helical and loop 
insertsl inserts that are observed throughout the CSF are located at the N or C-
terminal end of the individual cupin fold and do not insert at locations within a 
given cupin core domain.  For example, there may be an α-helix between two 
cupin domains of a bicupin as for lyxose isomerase but the beta strands of the 
individual cupin domains are consecutive and uninterrupted.  An exception to this 
trend is found in the PMI enzymes where an alpha helical insert is found in the N-
terminal cupin domain.  The topology diagrams also show that while the location 
of the ligand and meta-binding sites are conserved in three-dimensional space, 
they come from different secondary structural elements (Figure 2.28) 
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Figure 2.28 Topology diagrams for CSF members showing metal-binding residues do not come from same 
structural motifs. A) NTD of oxalate decarboxylase (PDB 1UW8). B) Lyxose isomerase (PDB 3HKM).  Black 
boxes show locations of metal binding residues 
      
 
103 
2.3.7 Comparison with other beta-barrel containing superfamilies 
The active sites for the CSF members reside inside the beta barrel. The 
largest known superfamily, the triosphosphate isomerase (TIM)  superfamily is 
composed of beta-alpha repeats that form a beta barrel with the alpha helices on 
the exterior of the protein88.  The active sites for this diverse superfamily are 
conserved in terms of their location within the TIM fold.  The active site resides 
on the C-terminal end and at the opening of the beta barrel89–91 (Figure 2.29A).  
This is in contrast to the CSF where the active site lies in the center of the beta 
barrel.  A second superfamily that contains a beta-barrel fold is the CDE 
superfamily that was named for the subclasses of enzymes that are found in the 
superfamily (chlorite dismutase, dye-decolorizing peroxidases (DyPs) and EFeBs 
(hemoproteins from E. coli)).91  This superfamily of enzymes all bind heme 
cofactors in the space between the beta barrel and the flanking alpha helices 
(Figure 2.29B).   
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Figure 2.129) Structures from two beta-barrel containing superfamilies. A) AdoMet radical enzymes superfamily 
member with Fe4S4 cluster and adomet bound (shown as sticks) (PDB ID 3CIK). B) CDE superfamily member IsdI 
with heme cofactor bound (shown as sticks) (PDB 3LGN). 
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2.3.8 Remapping of Uberto et. al. metal annotation onto SSN 
The PDB structures that contain the wrong metal were mapped onto our 
SSN (Figure 2.30).  A few of the improperly assigned metals overlap with clusters 
containing structures from the GSS.  Primarily Mn(II) and Zn(II)-containing 
proteins annotated from PDB structures fall within clusters containing Fe(II)-
binding proteins. We predict these are, in fact, Fe(II) dependent proteins. 
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Figure 2.30) Sequence similarity network for cupin superfamily displayed at an e-value of -20.  A) Representative 
nodes containing proteins in the gold standard set are indicated by boxes colored by metal ion. Fe(II) is magenta, 
Mn(II) is green, Zn(II) is yellow and non-metal proteins are black. B) Remapped incorrectly annotated metal-binding 
proteins from the PDB.  Circles indicate sequences which mapped onto clusters containing proteins known to bind 
Fe(II) 
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 Mapping of the improperly annotated metals from the PDB onto the 
SSN reveals five clusters where an improperly annotated metal clusters with a 
sequence from the GSS.  Unfortunately, at this time there is not sufficient 
literature or consistent sequence annotation to make insights into the identity of 
the proteins within these clusters with the exception of the cluster containing PDB 
ID 3GZE and 3ITQ.  The cluster containing PDB ID 3GZE with Zn(II) bound lies 
in a cluster containing Fe(II)-bound prolyl 4-hydroxylase (PDB ID 3ITQ)  from the 
GSS (Figure 2.29).  This cluster contains many unannotated sequence however 
the structures for both 3GZE and 3ITQ are characterized prolyl 4-hydroxylase 
enzymes.  Given that this cluster is known to have 55% sequence similarity it is 
likely that this cluster contains other prolyl 4-hydroxylase enzymes.  
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Figure 2.13: A)Remapped incorrectly annotated metal-binding proteins from the PDB cluster containing prolyl 
4-hydroxylases is indicated with an arrow. B) Expansion of the cluster containing prolyl 4-hydroxylases.  
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2.3.9 Future work 
Future work will include full sequence alignments for all sequences within 
a given cluster.  This may provide insights into conserved residues that may 
allow for identification of conserved motifs that assist prediction of metal 
incorporation, substrate binding-residues, well as catalytic residues.  Nearest-
neighbor gene networks could also prove to be useful should certain metal-
binding proteins require additional proteins to assist in metalation as well as 
annotation of clusters.  
2.3.10 Conclusions 
The SSN shows no overlap with different metals in the same cluster as 
opposed to the results suggested by Uberto et. al..  This is likely due to both the 
use of a sequence-based network as well as a well-curated data set of standard 
proteins (GSS).  The cupin proteins which show very similar functions tend to 
cluster together (ie non-metal sugar isomerase enzymes and SSP), having 
perhaps evolved from a common progenitor that dispensed with its metal 
dependence.  In many cases, both the metal-binding and ligand-binding site are 
conserved in the beta barrel regardless of the identity of the ligand or metal ion. 
Future work will include investigation of the numerous and very diverse Fe(II) 
dependent proteins from the CSF and comparison to the above described CSF 
members.   
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Chapter 3: An LBT-labeled epidermal growth factor for facile 
quantification of epidermal growth factor receptors 
3.1 Introduction to lanthanide-binding tags 
  Lanthanide ions possess a unique set of photochemical and 
electronic properties that have been exploited in biochemical systems to provide 
information on protein structure, function and dynamics.  Peptide-based 
lanthanide-binding tags are especially attractive due to the ease of incorporation 
into proteins of interest using standard molecular biology techniques.  Work in 
the Imperiali and Allen labs have focused on the development of lanthanide-
biding tags (LBTs) which are short peptides ranging from 17-20 amino acids that 
have high selectivity and affinity for lanthanide (Ln(III)) ions92–95.  LBTs have 
been utilized in NMR96,97 and X-ray crystallographic98,99 structure determination, 
as contrast agents for MRI100, and in studies on protein trafficking and 
localization101, protein dynamics102,103, protein-ligand interactions104–106, and 
enzymology107.   The work in this chapter discusses the use of a LBT-labelled 
EGF for quantification of EGFR in cells with the long-term goal of quantification in 
human tissues.  
3.1.1 Lanthanide luminescence  
The unique luminescent properties of Ln ions arise from the 4f valence 
electrons which are shielded from environmental effects, such as ligands, by the 
outer 5s and 5p electrons.  The sharp, narrow bands in Ln ion absorption and 
emission spectra are due to ff transitions.108  These transition are Laporte 
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forbidden which results in low molar absorptivities (~10 M-1cm-1) yet long 
millisecond excited state lifetimes.109   The low molar absorptivity can be 
circumvented by utilization of a sensitizing ligand.  The sensitizing ligand can 
transfer energy from its triplet state to a lower lying excited state of the Ln ion 
(Figure 3.1).    
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Figure 3.1: Diagram of Ln luminescence via a sensitizing agent.  A 
represents excitation of the sensitizer, B fluorescence of ligand, C 
phosphorescence of excited ligand and D luminescence of Tb(III) ion 
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3.1.2 Development of lanthanide-binding tags 
 The unique photophysical and electronic properties of Ln ions make 
them especially appealing for use in biophysical methods.  Therefore, was of 
particular interest to find a method to incorporate Ln ions into proteins.  It was 
observed that Ln ions can substitute in calcium-binding proteins due to their 
similar ionic radius and oxophilicity, however this application was limited to this 
small subset of proteins.110,111  Notably, these early studies identified two 
requirements for lanthanide luminescence: (1) the lanthanide ion must be fully 
coordinated by ligands to exclude water in order to avoid Dexter quenching 
through O-H bond vibrations and (2) a suitable sensitizing antennae must be 
within 5-10 Å of the lanthanide ion for proper energy transfer.   
Several groups achieved improved lanthanide affinity and luminescence 
intensity with site-specific modification of lanthanide-binding residues as well as 
the sensitizing aromatic amino acid.112  Imperiali and coworkers achieved a 
lanthanide-binding tag sequence with highest affinity for terbium which could be 
easily incorporated into proteins via standard molecular biology techniques.93  
Their method included both combinatorial library screening of synthetic peptides 
as well as rational design that included the incorporation of a tryptophan as the 
sensitizing ligand.  These studies resulted in LBTs with high luminescence 
intensity along with a binding affinity of ~40 nM.   The structure of the LBT was 
revealed the structure-activity relationship for LBT luminescence and affinity.  
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The Tb(III) ion is fully 8-coordinated by amino acid ligands including one main 
chain interaction from the carbonyl group of the tryptophan residue.  The 
sensitizing tryptophan is also located 7 Å from the Tb(III) metal center allowing 
for efficient energy transfer to the metal.  
 
3.1.3  Incorporation of LBTs into full-length proteins.  
Having an optimized LBT sequence the next challenge was incorporate 
the LBT into proteins without altering the protein structure and function.  Ubiquitin 
was used as a test case as its structure is well-studied.  N-terminally labelled 
LBT-ubiquitin proved that LBTs could be added to the terminal ends of proteins 
without altering protein structure as revealed by NMR studies.97  However, the N-
terminally labeled LBT-ubiquitin was too disordered to allow for phasing for X-ray 
crystallography structure determination97.   A ubiquitin construct was then 
generated with a double lanthanide binding tag where two consecutive LBTs 
were cloned onto the N-terminus of ubiquitin (dLBT-ubiquitin) in hopes on 
increasing rigidity of the LBT to allow for crystallization and high-resolution 
structure determination. Indeed, the dLBT resulted in increased rigidity as well as 
stabilizing contacts with the ubiquitin portion of the construct that allowed for a 
2.6 Å structure of the dLBT-ubiquitin to be solved via anomalous phasing from 
the bound Tb(III)99.  Due to the small size and compact shape, LBTs have been 
successfully incorporated into loop regions of proteins as well without disrupting 
protein structure and function.98,113 
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3.1.4 Luminescence studies using LBT labelled proteins 
The luminescence properties of lanthanide ions make the LBT a very 
attractive tag for use in fluorescence spectroscopy studies.  Lanthanide ions 
have long-lived (ms) excited states.109  Time-gated experiments allow for the 
elimination of background fluorescence thus increasing the sensitivity of 
measurements.114  Lanthanide ions have narrow emission bands in the visible 
spectrum with large Stoke’s shifts (>200 nm) making them potentially useful in in 
vivo studies.115   
LBTs have been used to study protein-protein interactions via lanthanide 
resonance energy transfer studies102–104.  Given the unpolarized nature of LBT 
emission, it has the potential to be applied to systems with significantly larger 
distances between donor and acceptor molecules (>100 Å) compared to typical 
FRET pairs116.  LBTs have been used in ligand binding studies of oubain, a 
potential drug for Na+/K+ ATPases via LRET between a LBT labelled Na+/K+ 
ATPase and a Bodipy-L1-lablled oubain107 providing a means of measuring 
affinity and of measuring the distance between the two labels.  LBTs have also 
been used to study protein delivery.117 LBT tagged proteins were visualized via 
fluorescence microscopy to study exogeneous protein trafficking into mammalian 
cells.   Overall, LBTs have been applied to a variety of systems exploiting their 
multi-functionality including NMR studies, protein crystallography and 
luminescence properties.   
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Given the previous work using LBTs, we aimed to expand upon these 
applications using an LBT-labelled cytokine, epidermal growth factor (EGF-LBT) 
to determine the ability of the LBT for in cellulo quantification of cell-surface 
receptors.  Successful use of the LBT for quantification of cell-surface receptors 
will lay the ground work for future use of such constructs such as cell imaging, 
ligand-receptor binding affinity or ligand-receptor complex crystal structure 
determination via anomalous phasing. 
3.2 Epidermal growth factor receptor quantification methods 
3.2.1 Biology of epidermal growth factor and its receptor  
Epidermal growth factor binds to epidermal growth factor receptor (EGFR) 
and plays a role in cell growth, proliferation, and differentiation.  EGF is a small 
protein of 53 amino acids (6045 Da) containing three intramolecular disulfide 
bonds. Epidermal growth factor receptor is the cell-surface receptor for a number 
of extracellular ligands including EGF, transforming growth factor, amphiregulin, 
betacellulin, epigen, and epiregulin.118 
Binding of EGF to EGFR is high affinity with a Kd ~5 nM.119,120 Upon EGF 
binding to EGFR, the receptor undergoes dimerization on the cell surface, 
although there is debate as to the existence of preformed dimers.121,122 Receptor 
dimerization is required for EGF induced cell signaling.  
Overexpression of EGFR has been cited as a phenotype in several 
cancers including prostate, ovarian, rectal and lung.123 Increased EGFR cell 
signaling events are related to tumor proliferation, angiogenesis, metastasis and 
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inhibition of apoptosis.124,125    EGFR expression levels have been related to 
cancer prognosis and reoccurance.126 Given the importance of EGFR in cancer, 
it is an attractive target for expression level studies and inhibition. 
3.2.2  EGFR quantification methods  
Various methods have been utilized to quantify EGFR levels in various cell 
types yet none are quantitate and also allow for cell recovery at high yields after 
experimentation. Radioactive 125I labeled EGF has been the most commonly 
utilized method for EGFR quantification.127,128 The 125I-EGF can be purchased or 
iodinated with relative ease.  Readout for this method involves scintillation 
counting.  While offering high sensitivity, this method requires expensive 
equipment and cumbersome safety procedures. Other methods have utilized a 
biotynilated EGF129, SPR130 and fluorescent anti-EGFR antibodies120,131,132. The 
antibody detection method has been used in confocal microscopy to quantify 
EGFR as well as to study the localization on the cell surface but requires 
conjugation to a second antibody for fluorescent readout.  Fluorescently labeled 
EGF or antibodies have very good brightness but this method has the drawback 
of high background fluorescence from endogenous fluors and label 
photobleaching.  Use of fluorescent probes in FACS allows for sorting of cells 
based upon label and the use of multicolor probes; yet recovery of cells for future 
experiments is poor. In this study we, sought to improve EGFR quantification by 
lanthanide luminescent readout utilizing LBTs using a method that is quantitative, 
direct, and allows cell recovery. 
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3.2.3 Production of EGF-LBT 
In cells, EGF is produced as a precursor protein of ~1207 amino acids and 
of 8 EGF-like sequences.  EGF also contains three disulfide bonds that together 
has made orthogonal expression of soluble and functional EGF difficult.  
Production of protein via refolding while difficult has been successfully worked 
out for EGF expressed in E. coli.133–135 The ability to make EGF via standard 
molecular biology techniques in the laboratory has opened up doors for tailoring 
the construct toward the researcher’s goals.   
Recently, Imperiali and coworkers have utilized recombinant EGF in 
combination with a semisythetic amino-acid linker to generate a fluorescent 
bivalent EGF molecule.136 In this study, two EGF constructs with a sortase 
recognition site encoded onto either the N and C terminal domain (see below for 
description of sortase reaction).  Following two sortase ligation steps a 
fluorescent bivalent EGF-LBT molecule was achieved.  The use of a sortase 
ligation step allows for the ligation of a synthetic LBT peptide that contains a 
sensitize amino acid of choice (ie tryptophan or a carbostyril derivative).  This 
semisynthetic sortase-coupling method proved successful for generating 
biologically active EGF constructs for studying EGFR activation.  
Given the success of the sortase ligation to generate fluorescent EGF 
constructs, we sought to create a LBT labeled EGF molecule for use in in cellulo 
studies.  A schematic of EGF-LBT synthesis is shown below in Figure 3.2.  
Sortase is an enzyme found in Gram-positive bacteria that functions in 
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attachment of proteins to the cell wall.137  Sortase requires a LPXTG recognition 
motif and a poly Gly acceptor.138,139  Use of a synthetic peptide such as the LBT 
peptide also allows for incorporation of unnatural amino acid as show in Figure 
3.2.  Unnatural amino acids are of particular interest for use in LBTs has certain 
sensitizing agents such a carbosytil 124 provide enhanced luminescence 
intensity140.  Production of EGF-LBT used in these studies was done by Andrew 
Krueger in the Imperiali lab.  The remainder of this chapter will describe the use 
of EGF-LBT for quantification of EGFR on A431 cells.  
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 Figure 3.2: Schematic for production of ligation of LBT to EGF via sortase A.  
Inset shows luminescence sensitizing agents that have been utilized with the 
LBT136 
      
 
121 
3.3 Materials and methods  
3.3.1 Cell culture 
A431 cells (ATCC) were cultured in Dulbecco’s modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 2 mM glutamine.  When cells reached 
~90% confluence they were detached using 0.06% trypsin solution.  Cells were 
seeded in 24-well tissue culture plates at a density of 10,000 cells/well and grown 
to confluence.   
3.3.2 EGF-LBT binding assay 
Once cells reached confluence, blocking buffer containing 10 mM HEPES, 
138 mM NaCl, 1% BSA and 0.5% NaN3, pH 7.2 was added to block non-specific 
sites.  Cells were incubated in blocking buffer overnight.  Cells were then washed 
three times with blocking buffer to remove excess media and potential phosphate 
contamination as phosphate chelates Ln ions.   
EGF-LBT, preincubated with 1.1 molar equivalents of TbCl3, was added to 
a final concentration of 500 nM.  The A431 cells were incubated with EGF-LBT-
Tb(III) for 30 mins at 4° C.   Unbound EGF-LBT-Tb(III) was removed by washing 
with 500 µL of blocking buffer three times.  Because luminescence intensity was 
not great enough for direct detection, a Tb(III) chelating agent with greater 
luminescence yield, cs-124-DTPA was added at 1 µM to bind and detect EGF-
LBT bound Tb(III) .  Tb(III) concentration was determined by luminescence 
intensity at 544 nm following excitation at 341 nm.  A standard curve of cs124-
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DTPA-Tb(III) was used to calculate EGFR concentration.  Total cell number was 
determined by hemocytometer following detachment via trypsin.   
To account for possible nonspecific binding, the experiment was repeated 
as above with an additional step with unlabeled EGF.  Cells were incubated with 
Tb-loaded EGF-LBT.  Following wash steps to removed excess EGF-LBT, EGF 
was added at varying concentrations between 0.1 nM and 100 nM.  Unlabeled 
EGF was allowed to equilibrate for 1-16 hours.  Unbound EGF and EGF-LBT 
was removed by washing twice with blocking buffer.  Cs-124 was added at 1 µM 
for Tb(III) chelation and quantification as described above.   
3.4 Results and discussion 
The LBT labelled EGF proved to be a successful tool for quantification of 
EGFR by Tb(III) luminescence.  Using the standard curve for Tb(III) 
concentration and the number of cells, the average EGFR/cell was determined to 
be 11.4 x106 EGFR/cell +/- 262,00Figure 3.3).  The error within experiments is 
very low indicating that this is a highly precise method of quantification.  Notable, 
the calculated EGFR per cell is higher than literature values of 1-3 million 
EGFR/cell measured by radiolabeled EGF, FACS or SPR imaging120,129,130.  
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Figure 3.3: A) Summary of data for quantification of EGFR via EGF-LBT.  B) 
calibration curve used to calculate Tb(III) concentration 
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 Efforts to account for non-specific binding by use of unlabeled EGF 
titrations have thus far been unsuccessful.  Cells with EGF-LBT-Tb(III) bound at 
90% max signal (10-fold above the Kd of ~5 nM) were incubated with unlabeled 
EGF at concentrations between 0.1-100 nM to compete for binding with bound 
EGF-LBT-Tb(III).  If a binding curve resulted in a Kd for EGF of ~5 nM, one could 
assume that the EGF-LBT-Tb(III) was in fact only bound to specific sites-EGFR.  
However, at an incubation period of 1 hr, no reduction in EGF-LBT-Tb(III) signal 
was observed meaning the unlabelleld EGF did not compete with the EGF-LBT-
Tb(III).  When the incubation time was extended to 3 hrs, the cells began to 
dissociate from the tissue culture plate therefore not allowing for wash steps to 
remove unbound EGF-LBT-Tb(III).  This form of a competition assay was chosen 
to minimize the amount of material needed for the experiments.  However, given 
the extended competition time for EGF binding this method was not successful.   
Future experiments will include pre-incubating A431 cells with high excess of 
unlabeled EGF (~1000 fold above Kd) followed by addition of EGF-LBT-Tb(III).  
Under these conditions the unlabeled EGF will occupy all specific sites and any 
signal from EGF-LBT results from non-specific binding that can then be 
subtracted from the signal to determine only signal from EGF-LBT-Tb(III) bound 
to EGFR.   
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Chapter 4: Application of lanthanide binding tags to X-ray fluorescence 
microscopy 
4.1 Introduction and background 
X-ray fluorescence microscopy (XFM) is emerging microanalytical 
technique that has been utilized for qualitative and quantitative mapping of 
metals in biological, materials and geological sciences141–143.  XRF studies have 
been primarily relegated to endogenous as they related to disease such as 
Ca(II)144, Zn(II)144, Fe(II), Fe(III)145 concentration and localization in Alzheimer’s 
and Parkinson’s disease.141 Other XFM-based methods have used gold 
nanoparticles to study tumor localization (GNP).146,147  The studies which utilize 
endogenous metals are limited to systems in which these metals are found as 
well as the high basal concentration within the cell.  GNP allow for studying tumor 
localization but does not provide any mechanistic information on the proteins 
involved.  This chapter describes the extension of the lanthanide-binding tag for 
use in XFM.  Use of the lanthanide-binding tag could allow for cell imaging, 
determination of protein localization, identification of protein-protein interactions 
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or endogenous metal incorporation within the cell via dual fluorescence 
monitoring.   
4.1.1 X-ray fluorescence microscopy basics 
X-ray fluorescence microscopy functions via the photoelectric effect where 
high energy electrons (> 1keV) ejects a core electron from the metal.  A higher 
shell electron then fills the vacancy and emits a photon with an energy equal to 
the difference in the binding energy between the two shells.  As the binding 
energy is dependent on the charge of the nucleus, the emission is distinct for 
each element, allowing for determineation of metal ion from the characteristic 
emission.  
XFM is a powerful analytical tool for studying trace elements of unknown 
identity.  Thelow limits of detection (~1 ppm) in whole cells or tissue sections 
allows for spatial-localization of trace-elements.148 Combination with orthogonal 
experiments such as X-ray fluorescence spectroscopy and X-ray absorption 
near-edge spectroscopy (XANES) allows for determination of not only metal 
identity but also oxidation state.141,149,150  These methods have been particularly 
useful for determining Fe oxidation state145,151 as well as localization of toxic 
metals such as Hg, Cd and Pb152–154. 
A great advantage of XFM in imaging over confocal microscopy are the 
short wavelengths achieved by use of X-ray raditation.  Given the small 
wavelengths used in XFM, wavelength-limited resolution, where the highest 
resolution achievable is approximately the half of the wavelength of radition used, 
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has been pursued as several institutions such as Deutsches Elektronen-
Synchrotron155, the synchrotron at Soleil156 and the Advanced Photon Source150 
with the goal of studying complex nanoscale structures in cells.  However, if one 
is going to study these systems in their near-native state, conventional sample 
preparation methods such as dehydration and fixing cells are not suitable as cells 
and cell components lose their 3D shape.  Additionally, given the high-energy 
photons required for this technique, radiation damage of the biological sample is 
a major obstacle.  Room temperature wet samples not only suffer from radiation 
damage, but they are also compromised by radiation-induced shrinkage which 
can result in artifacts due to diffusion of biomolecules and metals across 
compromised membranes.  Although this limitations can be mitigated by the use 
of dehydrated samples, the loss of water results in distortion of cellular structure 
and loss of some three-dimensional information.157–159 
Since both wet and dehydrated samples accumulate significant radiation 
damage over the time course of the XFM experiment, recent work has focused 
on the use of frozen samples to minimize the effects of ionizing radation. 
Freezing samples at liquid nitrogen temperature (~100 K) creates vitrified water 
allowing for preserving samples in their near-native state.160,161  New 
instrumentation, such as the Bionanoprobe at APS and the upcoming XFM 
beamline at NSLS II, have developed sample handling systems which allow for 
the freezing and maintaining of samples under cryogenic conditions.  These 
beamlines allow for studying frozen cells in a near-native structural state thus 
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improving upon the resolution potential of XFM as well as furthering the biological 
information to be gained from such experiments.    
New beamline set-ups that allow for higher resolution and conditions 
which allow for near-native state imaging opens many doors to systems which 
have not yet been investigated via XFM.  However, given the limited use of 
endogenous metals or gold nanonparticles for visualization, localization and 
concentration studies, there is great need for a fluorescent probe for XFM.  If a 
metal-based label for XFM could be developed analogous to what GFP was for 
fluorescence microscopy, the amount of systems to which this method could be 
applied expands immensely.  The LBTs are an interesting candidate for such a 
probe given its ability to chelate lanthanide metal ions as well as ease of 
incorporation into proteins of interest via stand molecular biology techniques (see 
Chapter 3).  Lanthanide ions in rocks and minerals, silica-aluminum catalysts and 
lanthanide concentrates and mixtures have been studied via XFS since the 
1950’s.162   Lanthanide ions have strong x-ray absorption near the L- and M-
edges at energies between ~1 and 100 keV making them applicable to XFM163.  
The present study describes the initial investigation of the applicability of LBTs as 
a probe from XFM. 
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4.2 Methods 
4.2.1 Construct design, cloning, and expression of LBT-OmpA and WT 
OmpA in E. coli 
Synthetic genes containing the WTOmpA and LBT-OmpA sequence 
optimized for protein expression in E. coli was purchased from Genewiz.  The 
gene was cloned via PCR into donor vector pDONR221 using primers: forward: 
GGGACAAGTTTGTACAAAAAAGCAGGTTCGAAAAAC 
CTGTATTTTCAGGGCAACCAACAACATCGGTGACGCA and reverse primer 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATGCGTCACCGATGTTGTT
GGT (Genewiz) and then inserted into pDONR221 then inserted into the 
expression vector pDEST14 via Gateway® cloning.164   
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Plasmids containing OmpA constructures were transformed into SoluBL21 
cells (Amsbio).  Expression protocols for WTOmpA and LBT-OmpA were the 
same.  Cultures were grown at 37 °C to and OD600 of 0.6-0.8 and induced with 1 
mM IPTG for 3 hours.  Following protein induction, cells were harvested by 
centrifugation at 3500 rpm.  Cells were then resuspended in wash buffer 
containing 150 mM NaCl and then pelleted again at 3500 rpm for 1 min.  Wash 
steps were repeated 3X to ensure removal of excess phosphate.  Following wash 
steps, the cells were incubated with 5 µM EuCl3 in 150 mM NaCl for 15 mins.  
Cells were once again pelleted and washed as before to remove excess Eu(III).  
Cells were then flash frozen in liquid nitrogen. 
4.2.2 Expression and preparation of dLBT-ubiquitin containing cells 
Cloning and expression of recombinant dLBT-ubiquitin were as previously 
described.100 Briefly,BL21 DE3 cells (NEB) were grown to an OD600 of 0.6-0.8 
and 37 °C and induced with 1 mM IPTG for 3 hr.  Cells were grown in the 
presence of 100 µM or 1 mM EuCl3 following protein induction to allow for uptake 
of Eu(III) into cells for LBT loading.  Following protein induction, cells were 
harvested by centrifugation at 3500 rpm and then washed in wash buffer as 
described above to remove excess Eu(III) from the cell surface.  Cells were then 
flash frozen in liquid nitrogen. 
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4.2.3  Preparation of A431 cells with EGF-LBT-Eu(III) 
The preparation of EGF-LBT is described in Chapter 3. A431 cells were 
cultured in 24-well tissue culture plates with 1 µm thick, 2 mm x 2 mm SiN 
windows located inside the wells.  Cells were grown in DMEM (ATCC) 
supplemented with 2 mM glutamine and 10% FBS. Cells were then incubated 
with 500 nM Eu-loaded EGF-LBT for 15 mins in wash buffer  (10 mM HEPES, 
138 mM NaCl, 5.5 mM sucrose, 1% sodium azide, pH 7.2) at 4 °C. After 
incubation, excess EGF-LBT was removed by washing with 1 mL wash buffer 
three times.  Cells were then fixed using paraformaldehyde.   
4.2.4 XFM data collection 
XFM data were collected by our collaborator, Dr. Lisa Miller,Brookhaven 
National Laboratories.  Images were acquired on the Bionanoprobe beamline at 
Argonne National Lab at room temperature and pressure in fly scan mode.  A 
750 mm by 350 area was scanned with monochromatic energy at 10 keV.  
Images were collected at a scan angle of 15° or 30° and integrated for 200-400 
ms per pixel.  
4.3 Results and discussion 
4.3.1 LBT-OmpA X-ray fluorescence microscopy 
As OmpA is one of the most highly expressed protein on E. coli cell 
membranes it was targeted as a proof of concept system to determine if LBTs 
could be used in XFM for cell imaging and protein localization studies165.  The 
amino-acid sequence for the transmembrane domain of E. coli OmpA and crystal 
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structure 1BXW166 were utilized to design a construct of OmpA in which the LBT 
would be contained in the extracellular loop containing residues 106-114 (loop 3, 
see Figure 4.1 X) in hopes that a LBT situated on the cell surface would allow for 
cell imaging and determination of LBT localization.  Two residues were removed 
from the middle of the loop, G110 and Y111 and the LBT sequence inserted 
between residues 109 and 112. The sequence and location of the LBT-inserted 
loop can be seen below in Figure 4.1.   . 
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Figure 4.1 Crystal structure of transmembrane portion of E. coli OmpA 
(PDB 1BXW) with loop targeted for LBT insertion shown in red. 
Broken main-chain segments are due to unmodeled loops in the 
original X-ray crystal structure.  Original sequence of OmpA from 
1BXW is shown in black with LBT insertion shown in red.  Deleted 
residues are in parentheses 
      
 
134 
  
Control samples included one in in which LBT-OmpA was expressed but 
no Eu(III) added during cell growth and a second in which  WT OmpA without an 
LBT was expressed in the presence of Eu(III).   XFM data were collected on the 
Bionanoprobe beamline at Argonne National Lab at and energy of 10 KeV.  
Samples were fixed and dried on SiN membranes and data collected at room 
temperature.  Fluorescence data were collected for chloride fluorescence to 
determine E. coli cell location on the SiN membrane as well as emission at the 
Eu(II) Lα1 edge (5848 eV) (.  XFM images of the experimental and control 
samples are shown in Figure 4.2.  
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 Figure 4.2: XFM images of E. coli OmpA.  Cells are imbedded in NaCl matrix. 
Cl images shows location of cells as dark "voids". Eu images shows location of 
Eu(III) ions as blue spots.  Merged images are an overlay of Cl and Eu images 
shows. A) LBT-OmpA expressing E. coli cells prepared with 5 µM EuCl3.  
Excess Eu(III) was not removed by wash steps. B) LBT-OmpA expressing E. 
coli cells prepared with 5 µM EuCl3.  Excess Eu(III) removed by wash steps. C) 
LBT-OmpA expressing cells with no Eu(III) present. D) WT OmpA expressing 
cells prepared with 5 µM EuCl3.  Eu(III) not removed by wash steps.  
      
 
136 
 The images in Figure 4.2 serve as proof of concept that LBTs 
loaded with Eu(III) could be used for cell visualization. Figure 4.2A clearly shows 
Eu(III) co-localization with the E. coli cells as well as the highest concentration of 
Eu(III) appearing on the membrane.  The chloride image shows the location of 
the cells as dark voids.  Eu(III) ions are shown as blue spots that overlap with the 
cells (dark voids). In samples expressing LBT-OmpA in which excess Eu(III) has 
be removed by washing (Figure 4.1B), a significantly lower concentration of 
Eu(III) is observed and the localization to the membrane is not as clear as Figure 
4.1A.  Control samples in which no Eu(III) was added to the cell mixture (Figure 
4.1C) show no Eu(III) present as indicated as no blue spots with intensity above 
background.  Additionally, E. coli cells expressing WT OmpA in the presence of 5 
µM EuCl3 do not show any specific localization of Eu(III) with the cells.  It is 
important to note that concentrations of Eu(III) in these images were not 
quantified. More work needs to be done to optimize loading of the LBT, number 
of wash steps and amount of nonspecific binding but these results show that the 
LBT with Eu(III) can be visualized via XFM providing a platform for future 
experiments.  
 To further confirm that the Eu(III) detected does in fact co-localize 
on the outer membrane where LBT-OmpA is located, tomography studies were 
completed. This allowed for a 3D reconstruction of the cells that could be 
segmented to determine the exact location of Eu(III) in the cell.  The 3D 
reconstruction was completed by Li Li at Argonne National Lab. Figure 4.3A 
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shows a 3D reconstruction of E. coli cells expressing LBT-OmpA in which excess 
Eu(III) had be removed via wash steps.  Figure 4.3B shows a “slice-through” of 
the 3D reconstruction of the cells in Figure 4.3A which clearly shows the 
localization of Eu(III) to the membrane of the cells.  This localization is consistent 
with the expected subcellular location LBT-OmpA and serves as a successful 
proof of concept experiment for the utility of the LBT in XFM.   
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Figure 4.3: Tomography 3D reconstructions of E. coli cells expressing LBT-
OmpA with Eu(III). A) 3D reconstuction of E. coli cells to 100 nm resolution. B) 
2-dimensional "slice-through" of E. coli cells in panel A. 
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4.3.2 XFM of dLBT-ubiquitin expressing E. coli cells 
Given the promising results of the E. coli cells expressing LBT-OmpA on 
the outer membrane, a cytosolic dLBT-ubiquitin construct was employed to 
determine if LBT-labeled proteins inside the cell could also be visualized via 
XFM. E. coli cells containing the plasmid for dLBT-ubiquitin were culture in LB 
growth medium with the addition of 1 mM EuCl3 in order to allow for uptake of 
Eu(III) for incorporation into the LBT.  Sample imaging and processing were as 
described for OmpA. Figure 4.4. shows XFM images of E. coli cells expressing 
dLBT-ubiquitin.   
  
      
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 Figure 4.4 XFM images of E. coli cells embedded in NaCl matrix A) expressing 
dLBT-ubiquitin grown in the presence of 1 mM EuCl3 and B) E. coli cells not 
expressing dLBT-ubiquitin grown in the presence of 1 mM EuCl3. The Cl images 
show location of cells in low Cl area as dark voids.  The Eu image show 
localization of Eu(III) and the merged image shows an overlay of the Cl and Eu 
images. 
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The images in Figure 4.4A clearly show the uptake and localization of 
Eu(III) within in the cells. It is likely that Eu(III) uptake into the cells occurs via 
Ca(II) transporters due to the similar ionic radius and oxophilicity of the metal 
ions although this remains to be verified.  This could be possible to verify by use 
of calcium transport inhibitors. Figure 4.4B demonstrates that without induction of 
expression from the plasmid carrying dLBT-ubiquitin gene the cells do not 
concentrate Eu(III) when grown under the same conditions as those in Figure 
4.4A.  Eu(III) concentrations in these images raged from 0.08-0.643 ug/cm2. 
These data demonstrate that the LBT can also be visualized via X-ray 
fluorescence microscopy when expressed within the cytosol of E. coli cells 
making the LBT applicable to both membrane-localized proteins as well as 
cytosolic proteins.   
4.3.3  XFM of A431 cells with EGF-LBT 
Next, we wanted to see if an exogenously added LBT protein could be 
incubated with cells and utilized in XFM imaging.  Use of the EGF-LBT construct 
as discussed in Chapter 3 showed that a LBT labelled EGF could be used for 
quantification of EGFR on cell surfaces.  A431 cells were chosen for these initial 
XFM experiments as they have the highest concentration of EGFR.  Cells were 
grown on SiN membranes prior to incubation with EGF-LBT-Eu(III).  Following 
incubation, unbound EGF-LBT-Eu(III) was removed via washing.  The cells were 
then fixed for to XFM experiments.  Figure 4.5 shows the reconstructed XFM 
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images for A431 cells imaged for K, Zn, and S and Eu  by X-ray fluorescence 
microscopy.   
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Figure 4.5: XFM images for A431 cells fixed and dried on SiN 
membranes with EGF-LBT-Eu(III) added extracellularly prior to 
fixation 
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Figure 4.5 clearly shows the outline of the A431 cells as evidence by 
fluorescence signals for K, Zn and S.  The Eu(III) concentration was at the lower 
limit of detection and uniformly distributed throughout the cell image.  More 
experiments are required to determine the proper procedure for binding of EGF-
LBT to the A431 cells as well as controlling for nonspecific binding of the EGF to 
the cell membrane.  The exact localization of the EGF-LBT-Eu(III) to the 
membrane vs. cytosol is not possible as the cells are flattened due to fixing and 
drying of the samples. While Eu(II) co-localized with the cells, the localization 
within the cells could not be determined.  In order to determine the localization of 
the EGF-LBT, samples need to be collected under cryogenic conditions in which 
cells a flash frozen to form a vitreous coating allow for visualization of the cells 
maintaining their 3D shape.148   
4.4 Conclusions 
The results presented above indicate that use of LBTs in XFM has great 
potential.  New XFM beamlines such as the Bionanoprobe at Argonne National 
Lab as well as the Hard X-ray Nanoprobe at NSLS II (to be commissioned Spring 
of 2016) offer substantial improvements in resolution (as high as ~15 nm) as well 
as conditions which allow for maintaining the 3D shape of cells.  This will allow 
for imaging complex nanoscale biological structures in their near-native states by 
utilizing frozen-hydrated samples.  The LBT shows great promise for use in XFM 
in a manner analogous to how green fluorescent protein (GFP) has been used 
extensively in confocal microscopy.  The LBT has distinct benefits over GFP as it 
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is much smaller (15-20 amino acids vs 25 kDa) and is therefore less likely to 
disrupt the native structure, function, and trafficking of proteins.  Additionally, it 
may be possible to tailor LBTs to selectively bind various metals to allow for 
tagging multiple proteins at the same time for a multi-color experiment.  Further 
studies are required to determine the detection limit of lanthanide-loaded LBTs 
and the nonspecific binding of lanthanides to other proteins in the cell.  
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 Appendices 
Appendix I) Sequence alignment for Bs OxDc and Cs OxOx. Identical 
residues are red and similar residues are yellow
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Appendix II) Sequence alignment for various OxOx orthologs.  Red 
coloring indicates identical residues and yellow conserved residues.  
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Appendix III) Curated gold standard set of cupins with structures in PDB 
Protein Species PDB Metal mono/bicupin oligomer 
Ara h 3, a major allergen in 
peanut 
Arachis hypogaea 2cv6 none bicupin hexamer 
Allergen Ara h 1, clone P41B Arachis hypogaea 3s7e none bicupin hexamer 
Beta-conglycinin Glycine max 1uij none bicupin trimer 
Proglycinin Glycine max 1fxz none bicupin trimer 
Glycinin Glycine max 1od5 none bicupin hexamer 
Prolegumin Pisum sativum 3ksc none bicupin trimer 
Prunin prunus dulcis 3ehk none bicupin hexamer 
Phaseolin Phaseolus vulgaris 2phl none bicupin tetramer 
Procruciferin Brassica napus 3kgl none bicupin trimer 
Alpha prime subunit of beta-
conglycinin 
Glycine max 1uik none bicupin trimer 
Seed storage protein Vigna radiata 2cv6 none bicupin trimer 
Canavalin/vinculin Canavalia 
ensiformis 
1dgw none bicupin trimer 
      
Dtdp-4-keto-6-deoxy-glucose-5-
epimerase evad 
Amycolatopsis 
orientalis 
1ofn none monocupin dimer 
Dtdp-4-dehydrorhamnose 3,5-
epimerase 
Bacillus anthracis 3ryk none monocupin dimer 
Dtdp-4-dehydrorhamnose 3,5-
epimerase 
Streptococcus suis 1nxm none monocupin dimer 
Dtdp-4-dehydrorhamnose 3,5- Sulfolobus tokodaii 1wlt none monocupin dimer 
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epimerase 
Dtdp-4-dehydrorhamnose 3,5-
epimerase 
Mycobacterium 
tuberculosis 
1upi none monocupin dimer 
Dtdp-6-deoxy-D-xylo-4-hexulose 
3,5-epimerase 
Pseudomonas 
aeruginosa 
1rtv none monocupin dimer 
Dtdp-4-dehydrorhamnose 3,5-
epimerase 
Salmonella 
typhimurium 
1dzr none monocupin dimer 
(dtdp)-4-keto-6-deoxy-d-hexulose 
3, 5-epimerase 
Methanobaterium 
thermoautotrophicu
m 
1ep0 none monocupin dimer 
Dtdp-6-deoxy-3,4-keto-hexulose 
isomerase 
Aneurinibacillus 
thermoaerophilus 
2pa7 none monocupin dimer 
4-Keto-6-deoxy sugar Epimerase 
(novw) 
Streptomyces 
spheroides 
2c0z none monocupin dimer 
      
1-aminocyclopropane-1-
carboxylate oxidase 
Petunia hybrid 1wa6 Fe monocupin tetramer 
Deacetoxycephalosporin C 
synthase 
Streptomyces 
clavuligerus 
1w28 Fe monocupin tbd 
Isopenicillin N synthase Emericella nidulans 1odm Fe monocupin monome
r 
Hypoxia-inducible factor prolyl 
hydroxylase (PHD2) 
Homo sapiens 2g19 Fe monocupin monome
r 
Ectoine hydroxylase (ectd) Virgibacillus 
salexigens 
3emr Fe monocupin monome
r 
Putative cytoplasmic protein Salmonella 2csg Fe monocupin monome
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typhimurium r 
Syringomycin biosynthesis 
enzyme 2 
Pseudomonas 
syringae 
2fct Fe monocupin monome
r 
3-Hydroxyanthranilate-3,4-
dioxygenase 
Cupriavidus 
metallidurans 
1yfu Fe monocupin dimer 
3-Hydroxyanthranilate-3,4-
dioxygenase 
Bos taurus 3fe5 Fe bicupin monome
r 
Putative cysteine dioxygenase Bacillus subtilis 3eqe Fe monocupin monome
r 
Hydroxypropylphosphonic acid 
epoxidase (fehppe) 
Streptomyces 
wedmorensis 
1zz7 Fe monocupin tetramer 
Gentisate 1,2-dioxygenase Pseudaminobacter 
salicylatoxidans 
3njz Fe bicupin tetramer 
Gentisate 1,2-dioxygenase Silicibacter 
pomeroyi 
3bu7 Fe bicupin tetramer 
Quercetin 2,3-dioxygenase Bacillus subtilis 1y3t Fe bicupin dimer 
Cytc3 Streptomyces sp. 3gja Fe monocupin monome
r 
Putative asparaginyl hydroxylase Bacillus subtilis 1vrb Fe monocupin dimer 
Factor inhibiting HIF1 Homo sapiens 2y0i Fe monocupin dimer 
Protein fto Homo sapiens 3lfm Fe monocupin monome
r 
Jmjc domain-containing histone 
demethylation protein 1A 
Homo sapiens 2yu2 Fe monocupin monome
r 
Jmjc domain-containing histone 
demethylation protein 3D 
Homo sapiens 3dxu Fe monocupin monome
r 
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Alkylated repair protein ALKB 
homolog 3 
Homo sapiens 2iuw Fe monocupin dimer 
PHD finger protein 2 Homo sapiens 3pu8 Fe monocupin monome
r 
Catalytic domain of PHD finger 
protein 8 
Homo sapiens 3k3n Fe monocupin monome
r 
PKHD-type hydroxylase TPA1 Saccharomyces 
cerevisiae 
3kt4 Fe bicupin monome
r 
Phytanoyl-coa dioxygenase 
domain-containing protein 1 
Homo sapiens 3obz Fe monocupin monome
r 
Cura halogenase Lyngbya majuscula 3nnf Fe monocupin dimer 
1-Deoxypentalenic acid 11-beta 
hydroxylase 
Streptomyces 
avermitilis 
2rdn Fe monocupin monome
r 
Alpha-ketoglutarate-dependent 
taurine dioxygenase 
Mycobacterium 
avium 
3r1j Fe unclear tetramer 
Taurine catabolism dioxygenase 
taud 
Mycobacterium 
marinum 
3swt Fe unclear monome
r 
L-arginine beta- hydroxylase Streptomyces  
vinaceus 
2wbp Fe monocupin monome
r 
Putative alkylsulfatase atsk Pseudomonas 
putida 
1oii Fe monocupin monome
r 
Carbapenem synthase (carc) Pectobacterium 
carotovorum 
1nx8 Fe moncupin hexamer 
Taurine/alpha-ketoglutarate 
dioxygenase (taud) 
Escherichia coli 1os7 Fe monocupin dimer 
Phosphoglucose isomerase Thermococcus 1j3p Fe monocupin dimer 
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litoralis 
Pirin Homo sapiens, 1j1l Fe bicupin monome
r 
Homogentisate dioxygenase Homo sapiens 1ey2 Fe unclear hexamer 
Anthocyanidin synthase Arabidopsis 
thaliana 
1gp6 Fe monocupin monome
r 
Cysteine dioxygenase type I Ralstonia eutropha 2gm6 Fe monocupin monome
r 
Cysteine dioxygenase type 1 Homo sapiens 2ic1 Fe monocupin monome
r 
Bacterial  cysteine dioxygenase Pseudomonas  
aeruginosa 
3uss Fe monocupin dimer 
Putative gentisate 1,2-
dioxygenase 
Escherichia coli 2d40 Fe bicupin tetramer 
Clavaminate synthase Stretomyces 
clavuligerus 
1dry Fe monocupin monome
r 
Type II Proline 3-hydroxylase Stretomyces sp., 1e5s Fe monocupin dimer 
Phytanoyl-coa 2-hydroxylase Homo sapiens 2a1x Fe monocupin monome
r 
Putative uncharacterized protein Caenorhabditis 
elegans 
3n9l Fe monocupin monome
r 
Lysine-specific demethylase 6B Homo sapiens 2xue Fe monocupin monome
r 
Jumonji domain-containing 
protein 2A 
Homo sapiens 2gp3 Fe monocupin monome
r 
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Auxin binding protein Zea mays 1lrh Zn monocupin dimer 
Transcriptional regulator, HTH_3 
family 
Vibrio cholerae 1y9q Zn monocupin dimer 
Anti-ecfsigma factor, chrr Marinobacter 
aquaeolei 
3o14 Zn bicupin monome
r 
Rpoe, ECF sige Rhodobacter 
sphaeroides 
2z2s Zn monocupin dimer 
4-Deoxy-L-threo-5-hexosulose-
uronate ketol-isomerase 
Escherichia coli 1xru Zn bicupin hexamer 
Mannose-6-phosphate isomerase Bacillus subtilis 1qwr Zn bicupin monome
r 
Mannose-6-phosphate isomerase Salmonella 
typhimurium 
3h1m Zn bicupin monome
r 
Phosphomannose isomerase Candida albicans 1pmi Zn bicupin monome
r 
      
Oxalate decarboxylase Bacillus subtilis 1uw8 Mn bicupin hexamer 
SLL1358 protein Synechocystis sp. 2vqa Mn bicupin hexamer 
D-lyxose isomerase Escherichia coli 
O157:H7 
3kmh Mn monocupin dimer 
Germin (Oxalate oxidase) Hordeum vulgare 2et1 Mn monocupin hexamer 
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Appendix IV) Structure-based sequence alignments for non-metal 
sugar isomerase enzymes in GSS
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Appendix V) Structure-based sequence alignment for all SSP in gold 
standard set
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Appendix VI) Structure-based sequence alignment for 11S SSP 
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Appendix VII) Structure-based sequence alignment for 7S SSP 
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Appendix VIII) Structure-based sequence alignment for Mn(II)-binding 
proteins in GSS 
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Appendix IX) Structure-based sequence alignment for Mn(II)-dependent 
OxDcs from GSS
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Appendix X) Structure-based sequence alignment for Zn(II)-binding 
transcription  factors from GSS 
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Appendix XI) Structure-based sequence alignment for Zn(II)-binding 
sugar isomerase enzymes from GSS 
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Appendix XII) Structure-based sequence alignment for Zn(II)-binding 
PMIs from GSS 
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Appendix XII) Topology diagrams for CSF subclasses 
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